<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2642</article-id>
         <article-id pub-id-type="publisher-id">2642</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Cardiovascular system</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Srce in ožilje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Pregledni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Srce in ožilje</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Zgodnji gigantocelični arteritis: čas od simptomov do diagnoze, možnosti zdravljenja in klinično značilna celična dinamika</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Early giant cell arteritis: Identifying duration from symptoms to diagnosis, possible therapies and clinically-relevant cell dynamics</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Zgodnji gigantocelični  arteritis</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Burja</surname>
                  <given-names>Blaž</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Hočevar</surname>
                  <given-names>Alojzija</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Sodin Šemrl</surname>
                  <given-names>Snežna</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff2">2</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Lakota</surname>
                  <given-names>Katja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Rotar</surname>
                  <given-names>Žiga</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Ješe</surname>
                  <given-names>Rok</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Žigon</surname>
                  <given-names>Polona</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Čučnik</surname>
                  <given-names>Saša</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Nadkarni</surname>
                  <given-names>Suchita</given-names>
               </name>
               <xref ref-type="aff" rid="aff4">4</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Peretti</surname>
                  <given-names>Mauro</given-names>
               </name>
               <xref ref-type="aff" rid="aff4">4</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Praprotnik</surname>
                  <given-names>Sonja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Tomšič</surname>
                  <given-names>Matija</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za revmatologijo, Intena klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Rheumatology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff2">
            <aff xml:lang="sl">
               <label>2</label>
               <institution>Fakulteta za matematiko, naravoslovje in informacijske tehnologije, Univerza na Primorskem, Koper, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>2</label>
               <institution>Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Koper, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff3">
            <aff xml:lang="sl">
               <label>3</label>
               <institution>Fakulteta za farmacijo, Univerza v Ljubljani, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>3</label>
               <institution>Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <aff-alternatives id="aff4">
            <aff xml:lang="sl">
               <label>4</label>
               <institution>William Harvey Research Institute, Queen Mary University of London, United Kingdom</institution>
            </aff>
            <aff xml:lang="en">
               <label>4</label>
               <institution>William Harvey Research Institute, Queen Mary University of London, United Kingdom</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Snežna Sodin Šemrl, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>8</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>8</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>7–8</issue>
         <fpage>335</fpage>
         <lpage>48</lpage>
         <history>
            <date date-type="received">
               <day>13</day>
               <month>8</month>
               <year>2017</year>
            </date>
            <date date-type="accepted">
               <day>30</day>
               <month>11</month>
               <year>2017</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Gigantocelični arteritis (GCA) je najpogostejši primarni sistemski vaskulitis pri odraslih po 50. letu starosti v Evropi. Prizadete so velike in srednje velike arterije. Vnetni proces, ki zožuje ali popolnoma zapre svetlino žile, lahko dovede do hudih in trajnih ishemičnih zapletov, kot so oslepitev, možganska kap ali miokardni infarkt. V zadnjem desetletju se je z vključitvijo slikovnih preiskav v diagnostični postopek pomembno skrajšal čas do prepoznave bolezni (t. i. zgodnji GCA). Pospešena obravnava bolnikov (<italic>angl.</italic> fast track clinic) je vodila v zmanjšanje pojavnosti najresnejših ishemičnih zapletov bolezni in k znižanju stroškov zdravljenja. Vendar pa bolezen praviloma poteka kronično, in sicer s poslabšanji, kar skupaj s kroničnim glukokortikoidnim zdravljenjem vodi v kopičenje okvar organov in tkiv. Prav zato se intenzivno preučuje patogeneza bolezni z možnostjo terapevtske uporabe izsledkov, kot je sodobno molekularno in celično usmerjeno tarčno zdravljenje. Glavni cilji našega preglednega članka so bili: a) analiza raziskav z navedenim časom trajanja od začetka simptomov do postavitve diagnoze, b) raziskava obetavnih molekularnih tarč za zdravljenje GCA in c) prepoznava klinično pomembnih celičnih podtipov. Najbolj obetavne tarčne molekule za tarčno zdravljenje so IL-6, IL-12/IL-23 in citototoksični z limfociti T povezan protein 4, medtem ko zdravljenje z zaviralci faktorja tumorske nekroze alfa (TNF-α) ni bilo uspešno. Kliničnih raziskav z učinkovinami, usmerjenimi proti IL-17, še ni. V prispevku pa smo se dotaknili tudi drugih možnih terapevtskih tarč, vključno z molekulami, ki sodelujejo v signalnih poteh.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Giant cell arteritis (GCA) is the most prevalent primary systemic vasculitis in adults over 50 years of age in Europe. It affects large and medium sized arteries; the inflammatory process can ultimately lead to stenosis or occlusion of arterial lumen, resulting in severe clinical complications. In the last decade, imaging in diagnostics has importantly shortened the time to disease recognition (e.g. early GCA). Fast track clinics have led to a decrease in appearance of the most severe ischemic disease complications and lower costs of therapy. Despite fast access to appropriate therapy, the disease is chronic, and patients can experience relapses, which together with glucocorticoid therapy may lead to organ and tissue damage. Therefore, viable molecular and cellular target therapies are intensely explored. The major aims of our review were to: a) identify studies with indicated time from symptom development to diagnosis, b) explore promising molecular targets for GCA therapy, and c) identify clinically-relevant cellular phenotypes. The most promising molecular targets are IL-6, IL-12/IL-23, cytotoxic T–lymphocyte-associated protein-4, while therapies against TNF-α showed limited value and no clinical studies with secukimumab targeting IL-17 in GCA have been reported to date. Potential future therapeutic targets have been discussed, including targets in signaling pathways.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>zgodnji gigantocelični arteritis</kwd>
            <kwd>biološki označevalci</kwd>
            <kwd>tarčno zdravljenje</kwd>
            <kwd>celični fenotip</kwd>
            <kwd>T-celice</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>early giant cell arteritis</kwd>
            <kwd>biomarkers</kwd>
            <kwd>therapy targets</kwd>
            <kwd>cellular phenotypes</kwd>
            <kwd>T cells</kwd>
         </kwd-group>
         <custom-meta-group>
            <custom-meta>
               <meta-name>TotalReferences</meta-name>
               <meta-value>98</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesParsed</meta-name>
               <meta-value>87</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBillable</meta-name>
               <meta-value>89</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LinkServices</meta-name>
               <meta-value>pubmed-crossref</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinked</meta-name>
               <meta-value>87</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedDOI</meta-name>
               <meta-value>81</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedPMID</meta-name>
               <meta-value>84</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>JournalReferences</meta-name>
               <meta-value>86</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookChapterReferences</meta-name>
               <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ConferenceReferences</meta-name>
               <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ElectronicReferences</meta-name>
               <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>DissertationReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LegalReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>StandardReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>OtherReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>UnknownReferences</meta-name>
               <meta-value>6</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesSemiParsed</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBookUnparsed</meta-name>
               <meta-value>1</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>EditorialStyle</meta-name>
               <meta-value>ICMJE-WHO</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Izhodišče">
         <label>1</label>
         <title>Izhodišče</title>
         <p>Sistematični pregled opisuje gigantocelični arteritis (GCA): klinični potek ter pomen zgodnje postavitve diagnoze in zdravljenja z namenom preprečevati zaplete bolezni, kot sta slepota in možganska kap.</p>
      </sec>
      <sec id="s2" sec-type="Uvod">
         <label>2</label>
         <title>Uvod</title>
         <p>Gigantocelični arteritis (GCA) je najpogostejši sistemski vaskulitis odrasle populacije (pri osebah nad 50 let) v zahodnem svetu (<xref ref-type="bibr" rid="b1">1</xref>). Gre za vnetno avtoimunsko bolezen s prevladujočo prizadetostjo velikih in srednje velikih arterij. Značilna je prizadetost vej zunanje karotidne arterije, kar pove tudi staro poimenovanje bolezni (“temporalni arteritis”) (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b3">3</xref>). Ta izraz kot sinonim za GCA so opustili že leta 1994 na konferenci v Chapel Hillu (<italic>angl.</italic> Chapel Hill Consensus Conference, CHCC). Bolezen namreč lahko prizadene tudi druge arterije, zlasti aorto in velike veje aortnega loka (npr. prizadetost podključničnih arterij, aksilarnih arterij, brahialnih arterij), kar prepoznava tudi posodobljena opredelitev bolezni na konferenci CHCC leta 2012 (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b5">5</xref>). Ocenjena prevalenca bolezni je pribl. 1:750 pri osebah, starejših od 50 let, medtem ko incidenca naraste za pribl. 25-krat med starostno skupino 50–59 in skupino starejših od 80 let (<xref ref-type="bibr" rid="b6">6</xref>). Letna incidenca GCA v Sloveniji se ocenjuje na 9,7 (95 % CI 8.1–15.5) /10<sup>5</sup> pri osebah, starejših od 50 let (<xref ref-type="bibr" rid="b7">7</xref>).</p>
         <p>Spol in rasa sta dejavnika tveganja za GCA, pri čemer je med bolniki 65–75 % žensk (<xref ref-type="bibr" rid="b8">8</xref>). Incidenca bolezni je najvišja pri populaciji belcev Severne Evrope (pribl. 20/10<sup>5</sup> oseb &gt; 50 let) in se zmanjšuje proti jugu. Zaradi poznega začetka bolezni se pripisuje vloga tudi dejavnikom okolja (kot npr. kajenje), ki vplivajo na dovzetnost za nastanek bolezni (<xref ref-type="bibr" rid="b8">8</xref>).</p>
         <sec id="s2.1" sec-type="Klinična slika">
            <label>2.1</label>
            <title>Klinična slika</title>
            <p>Klinična slika GCA obsega širok spekter raznolikih simptomov, ki so lahko posledica sistemskega vnetja in se kažejo s splošnimi simptomi in znaki, ali pa so neposredno povezani z ishemijo, ki je posledica slabše prehodnosti arterij in povzroči specifične znake bolezni (<xref ref-type="bibr" rid="b3">3</xref>). Med specifičnimi znaki je najbolj pogost novonastali glavobol. Bolniki pogosto navajajo tudi klavdikacijske bolečine ob žvečenju v žvečnih mišicah, občutljivost lasišča in bolečine med česanjem. Pri bolnikih lahko opazimo zadebeljeno in na pritisk bolečo temporalno arterijo. Zaradi zapore arterij, ki prehranjujejo oko, lahko pride do motenj vida. Te se najpogosteje kažejo kot dvojni vid, megleni vid, nenadna prehodna (amaurosis fugax) ali trajna izguba vida. Pred trajno izgubo vida se pogosto pojavijo ostale prehodne motnje vida, zato moramo biti na takšne opozorilne znake pozorni. S pravočasnim zdravljenjem lahko preprečimo trajno oslepitev. Nezdravljeni bolniki z enostransko oslepitvijo imajo 50-odstotno tveganje, da v nekaj dneh oslepijo še na drugo oko (<xref ref-type="bibr" rid="b9">9</xref>). Rezultati velike metaanalize so pokazali, da sta klavdikacija žvečnih mišic in dvojni vid najboljša napovedna dejavnika GCA (<xref ref-type="bibr" rid="b10">10</xref>). Zaradi velikega tveganja za nastanek trajne slepote (14–20 % bolnikov) (<xref ref-type="bibr" rid="b11">11</xref>-<xref ref-type="bibr" rid="b13">13</xref>) in možganske kapi (2–4 % bolnikov) (<xref ref-type="bibr" rid="b14">14</xref>) uvrščamo GCA med urgentna stanja v revmatologiji.</p>
            <p>V 30–83 % so lahko pri bolnikih prizadete tudi velike arterije, kar se najpogosteje kaže s klavdikacijami mišičja udov in nesimetričnimi ali odsotnimi pulzi na udih (<xref ref-type="bibr" rid="b15">15</xref>). V 10–18 % so ugotovili tudi prizadetost aorte, ki lahko vodi do nastanka anevrizme in aortne disekcije (<xref ref-type="bibr" rid="b15">15</xref>). Značilnost bolezni je tudi sistemsko vnetje s povišanimi vnetnimi parametri, ki lahko prevladuje v klinični sliki s splošnimi simptomi, kot so vročina, hujšanje, neješčnost, utrujenost, mialgije.</p>
            <p>Revmatična polimialgija (PMR) je tesno povezana z GCA, saj se pojavlja pri 40–50 % bolnikov z GCA (<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>). Nasprotno pa lahko GCA najdemo pri 15 % bolnikov s PMR (<xref ref-type="bibr" rid="b18">18</xref>). Obe bolezni sta namreč povezani in nekateri ju opisujejo kot dva pojava iste bolezni.</p>
         </sec>
         <sec id="s2.2" sec-type="Diagnoza">
            <label>2.2</label>
            <title>Diagnoza</title>
            <p>Starost nad 50 let je eden od 5 klasifikacijskih meril za GCA, ki jih je objavilo ameriško združenje revmatologov ACR (American College of Rheumatology). Ostala so: nastanek novega glavobola, klinično spremenjena temporalna arterija, pospešena sedimentacija eritrocitov (ESR ≥ 50 mm/h) in patološka biopsija temporalne arterije (<xref ref-type="bibr" rid="b19">19</xref>). Za opredelitev vaskulitisa kot GCA mora biti prisotnih vsaj 3 od 5 meril, ob tem dosežemo 93-odstotno občutljivost in 91-odstotno specifičnost. Potrebno je poudariti, da to niso diagnostična pač pa razvrstitvena merila, ki ne omogočajo zgodnje prepoznave. Uporabljamo jih le kot pomoč pri diagnostični obravnavi. Diagnoza bolezni pa je klinična (<xref ref-type="bibr" rid="b20">20</xref>).</p>
            <p>Še do nedavnega je bila biopsija temporalne arterije edini »zlati standard« za potrditev diagnoze GCA. Vendar pa danes vemo, da tolmačenje histopatoloških najdb v žilni steni ni enostavno, da je žilno vnetje segmentno (in lahko pri biopsiji arterije zgrešimo vneti segment) in da je biopsija temporalne arterije v več kot polovici primerov zunajlobanjske prizadetosti negativna. Tako dandanes biopsija temporalne arterije kot glavna in edina potrditvena metoda GCA izgublja na pomenu (<xref ref-type="bibr" rid="b8">8</xref>). Sodobno diagnosticiranje bolezni temelji na slikovnih preiskavah, kot so ultrazvočna preiskava (UZ) arterij, računalniško tomografska oz. magnetnoresonančna (CT/MR) angiografija in pozitronska emisijska tomografija (PET/CT). Te preiskave omogočajo poleg postavitve diagnoze in zamejitve bolezni vsaj deloma tudi njeno sledenje. Prve tri preiskave nam omogočajo dobro oceno strukturnih sprememb (ocena zadebeljene žilne stene, zožitve/zapore, tromboze ipd.), PET pa zgodnjo oceno funkcijske/vnetne aktivnosti bolezni v žilni steni – lahko še pred nastankom strukturnih sprememb. Med slikovnimi tehnikami ima prednost UZ preiskava, ker je neinvazivna, široko dostopna, poceni in bolnika ne obremenjuje z ionizirajočim sevanjem. Z njo lahko dobro ocenimo vse velike arterije, razen torakalne aorte. UZ najdba, značilna za GCA, je znak »halo« s pozitivnim testom stisljivosti (gre za vneto zadebeljeno žilno steno, ki ne izgine ob kompresiji arterije). Prva multicentrična raziskava o uporabnosti UZ pri diagnosticiranju GCA (TABUL) je potrdila pomembno vlogo UZ-preiskave pri zgodnjem prepoznavanju bolezni. Pokazala je, da ima UZ-preiskava temporalne arterije boljšo občutljivost in primerljivo specifičnost kot biopsija temporalne arterije (<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>). UZ-sledenje je pomembno za napoved izida zdravljenja (<xref ref-type="bibr" rid="b23">23</xref>), PET/CT je poleg UZ-preiskave pomembna diagnostična metoda pri sumu na prizadetost zunajlobanjskih velikih žil, ki se pogosto kaže z vročino nejasnega izvora ali nepojasnjenim vnetnim sindromom. Slikanje PET omogoča razmejitev bolezni, vloga pri napovedi izida zdravljenja pa še ni jasna (<xref ref-type="bibr" rid="b23">23</xref>).</p>
         </sec>
         <sec id="s2.3" sec-type="Zdravljenje">
            <label>2.3</label>
            <title>Zdravljenje</title>
            <p>Glukokortikoidno (GK) zdravljenje učinkovito umiri sistemsko vnetje in v večini primerov prepreči nastanek akutnih zapletov, npr. trajne slepote. Kljub temu približno 50 % bolnikov doživi poslabšanje bolezni med zniževanjem odmerka GK (<xref ref-type="bibr" rid="b24">24</xref>). Za vzdrževanje remisije aktivno iščejo nova zdravila (<xref ref-type="bibr" rid="b25">25</xref>). Priporočila Evropske lige za boj proti revmatizmu (EULAR) iz leta 2008 za zdravljenje GCA vključujejo tudi uporabo imunosupresivne učinkovine, da bi zniževali stranske učinke glukokortikoidov in vzdrževali boljši nadzor bolezni (<xref ref-type="bibr" rid="b26">26</xref>). Metotreksat (MTX) se pogosto uporablja pri ponovitvah bolezni kljub preteklim podatkom o nizki učinkovitosti, saj novejše študije poročajo o znatnem zmanjšanju števila poslabšanj (relapsov) ob zgodnjem dodajanju MTX ob GK (<xref ref-type="bibr" rid="b27">27</xref>-<xref ref-type="bibr" rid="b30">30</xref>). Posamezni avtorji kot sredstvo za zniževanje uporabe GK uporabljajo tudi leflunomid (<xref ref-type="bibr" rid="b31">31</xref>). Nedavno je ameriška agencija za hrano in zdravila (Food and Drug Administration, FDA) odobrila uporabo monoklonskega protitelesa proti receptorju za interlevkin (IL) 6 (tocilizumab) kot prvo tarčno biološko zdravilo za zdravljenje GCA (<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b33">33</xref>); potekajo pa tudi študije z zaviralcem IL-12/23 (ustekinumab) (<xref ref-type="bibr" rid="b34">34</xref>,<xref ref-type="bibr" rid="b35">35</xref>).</p>
         </sec>
      </sec>
      <sec id="s3" sec-type="Zgodnji GCA">
         <label>3</label>
         <title>Zgodnji GCA</title>
         <p>Zgodnja diagnoza in hitro zdravljenje GCA ključno vplivata na izid bolezni (<xref ref-type="bibr" rid="b36">36</xref>). Zato smo zbrali podatke raziskav, ki navajajo čas trajanja od začetka simptomov do postavitve diagnoze (<xref ref-type="table" rid="table1">Tabela 1</xref>). Izbrane raziskave vključujejo raziskave od leta 2010 dalje, ki vključujejo vsaj 20 bolnikov (<xref ref-type="bibr" rid="b24">24</xref>,<xref ref-type="bibr" rid="b37">37</xref>-<xref ref-type="bibr" rid="b47">47</xref>). Večina raziskav kaže, da je čas trajanja do postavitve diagnoze daljši od enega meseca. Najhitrejšo postavitev diagnoze so v letu 2016 opisali Carrbonella A in sodelavci (<xref ref-type="bibr" rid="b37">37</xref>) s povprečnim časom trajanja do diagnoze 3 (± 1.9) tedne in Hočevar A in sodelavci (<xref ref-type="bibr" rid="b24">24</xref>) z mediano vrednostjo 30 dni (interkvartilni razpon 12–71). To je pomembno predvsem zaradi hitrejšega začetka zdravljenja in s tem z večjo možnostjo, da se preprečijo resni zapleti. Bolniki v različnih državah se k revmatologu napotijo različno hitro. V nekaterih državah bolnike že pred napotitvijo k revmatologu zdravijo družinski zdravniki z GK, medtem ko imajo nekatere države hitre specializirane klinike za GCA, ki omogočajo hitrejšo postavitev diagnoze.</p>
         <table-wrap position="anchor" id="table1">
            <label>Tabela 1:</label>
            <caption>
               <p> Raziskave, ki opredeljujejo čas od začetka simptomov do postavitve diagnoze GCA. </p>
            </caption>
            <table>
               <colgroup>
                  <col/>
                  <col/>
                  <col/>
                  <col/>
               </colgroup>
               <thead>
                  <tr>
                     <th>Vir</th>
                     <th>Naslov</th>
                     <th>
                        <p># GCA</p>
                        <p>bolnikov</p>
                     </th>
                     <th>Trajanje od začetka simptomov do diagnoze</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Carbonella A. et al., J Am Geriatr Soc. 2016 (<xref ref-type="bibr" rid="b37">37</xref>)</td>
                     <td>Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of GCA: Comparison with Corticosteroids Alone</td>
                     <td>47</td>
                     <td>3,0 ± 1,9 tednov</td>
                  </tr>
                  <tr>
                     <td>Hocevar A. et al., Medicine<italic> </italic>(Baltimore), 2016 (<xref ref-type="bibr" rid="b24">24</xref>)</td>
                     <td>Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study</td>
                     <td>68</td>
                     <td>30 (14–71) dni</td>
                  </tr>
                  <tr>
                     <td>Seelinger B et al., Rheumatology, 2015 (<xref ref-type="bibr" rid="b38">38</xref>)</td>
                     <td>Predictors of Delay in Diagnosis of Giant Cell Arteritis and Antineutrophil Cytoplasm Antibody Associated Vasculitides: Analysis of Data from the Diagnostic &amp; Classification Criteria in Vasculitis Study</td>
                     <td>230</td>
                     <td>31 (13–85) dni</td>
                  </tr>
                  <tr>
                     <td>Ezeonyeji A.N. et al., Clin Rheumatology, 2011 (<xref ref-type="bibr" rid="b39">39</xref>)</td>
                     <td>Delays in recognition and management of GCA: results from a retrospective audit</td>
                     <td>65</td>
                     <td>35 (2–140) dni</td>
                  </tr>
                  <tr>
                     <td>Chandran A.K. et al., Scand J Rheumatol, 2015 (<xref ref-type="bibr" rid="b40">40</xref>)</td>
                     <td>The Incidence of GCA in Olmsted County Minnesota, Over a Sixty Year Period 1950–2009</td>
                     <td>74</td>
                     <td>1,6 ± 2,6 meseca</td>
                  </tr>
                  <tr>
                     <td>Baldini M. et al., Arthritis &amp; Rheumatism, 2012 (<xref ref-type="bibr" rid="b41">41</xref>)</td>
                     <td>Selective Up-Regulation of the Soluble Pattern-Recognition Receptor Pentraxin 3 and of VEGF in GCA</td>
                     <td>30</td>
                     <td>
                        <p>1,90 ± 0,35</p>
                        <p>(0,12–8) mesecev</p>
                     </td>
                  </tr>
                  <tr>
                     <td>Ciccia F. et al., Ann Rheum Dis, 2016 (<xref ref-type="bibr" rid="b42">42</xref>)</td>
                     <td>Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in GCA</td>
                     <td>50</td>
                     <td>2 ± 11 mesecev</td>
                  </tr>
                  <tr>
                     <td>Labarca C. et al., Rheumatology (Oxford), 2016 (<xref ref-type="bibr" rid="b43">43</xref>)</td>
                     <td>Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study</td>
                     <td>286</td>
                     <td>2,1 (0,9–4,4) mesec</td>
                  </tr>
                  <tr>
                     <td>Muller G. et al., Geriatr Gerontol Int, 2015 (<xref ref-type="bibr" rid="b44">44</xref>)</td>
                     <td>GCA (Horton‘s disease) in very elderly patients aged 80 years and older: A study of 25 cases</td>
                     <td>25</td>
                     <td>2,2 meseca</td>
                  </tr>
                  <tr>
                     <td>Muratore F. et al., Rheumatology (Oxford), 2015 (<xref ref-type="bibr" rid="b45">45</xref>)</td>
                     <td>Large-vessel GCA: a cohort study</td>
                     <td>120 LV-GCA</td>
                     <td>3,5 (2–7,2) mesecev</td>
                  </tr>
                  <tr>
                     <td>Alba MA. et al., J Clin Rhematol. 2012 (<xref ref-type="bibr" rid="b46">46</xref>)</td>
                     <td>GCA in Mexican patients</td>
                     <td>22</td>
                     <td>67 ± 83,6 dni</td>
                  </tr>
                  <tr>
                     <td>Alba M.A. et al., Medicine (Baltimore). 2014 (<xref ref-type="bibr" rid="b47">47</xref>)</td>
                     <td>Relapses in Patients with GCA: Prevalence, characteristics and associated clinical findings in a longitudinally followed cohort of 106 patients</td>
                     <td>106</td>
                     <td>16 ± 21 tednov</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Legenda: BAFF: Aktivirajoči faktor B-celic; CXCL13: chemokinski (C-X-C motif) ligand 13; NA: not available; HBD: apparently healthy blood donors; GCA: gigantocelični arteritis; LT-β: Limfotoksin-beta; LV-GCA: GCA velikih žil; PMR: revmatična polimialgija. The data was taken from sources »ad verbum«.</p>
            </table-wrap-foot>
         </table-wrap>
         <p>Vendar se predvsem z očesnimi zapleti pokaže malce drugačna slika. Singh in sodelavci so leta 2015 poročali, da ni bilo prisotnih razlik v času trajanja od nastanka simptomov do postavitve diagnoze med bolniki z očesnimi zapleti ali brez njih (mediana 26 in 24 dni) (<xref ref-type="bibr" rid="b48">48</xref>). Daljša, 25-letna longitudinalna raziskava, narejena v Španiji, poroča o času do diagnoze 10,3 (± 11) tednov (<xref ref-type="bibr" rid="b49">49</xref>). Njihovi rezultati kažejo, da zmanjšanja pogostnosti očesnih zapletov ni mogoče pripisati krajšemu času do postavitve diagnoze. Vendar najnovejše raziskave nakazujejo nasprotno, med njimi so tudi Hočevar in sodelavci poročali o enostranski slepoti pri 5,9 % (4/68) bolnikih z GCA. V zadnjih letih je mogoče opaziti upad števila primerov trajne slepote, predvsem zaradi večje ozaveščenosti zdravnikov, saj lahko zgodnja prepoznava bolezni prepreči razvoj hujših posledic (<xref ref-type="bibr" rid="b50">50</xref>). Zgodnje odkritje bolezni in hiter začetek zdravljenja z glukokortikoidi je ključ do zmanjševanja teh resnih zapletov.</p>
      </sec>
      <sec id="s4" sec-type="Tarčne molekule pri zdravljenju GCA">
         <label>4</label>
         <title>Tarčne molekule pri zdravljenju GCA</title>
         <p>Trenutno se za zdravljenje GCA uporabljajo visoki začetni odmerki GK, ki so zelo učinkoviti. Odmerek se nato postopoma znižuje. Celotno zdravljenje običajno traja 2 leti. Zaradi stranskih učinkov dolgotrajnega zdravljenja z glukokortikoidi (GK) in pogostih poslabšanj bolezni ob zniževanju odmerka se aktivno iščejo nove terapevtske možnosti. Možne terapevtske tarče so tako citokinske kot tudi necitokinske molekule.</p>
         <sec id="s4.1" sec-type="Citokinske tarčne molekule za zdravljenje GCA">
            <label>4.1</label>
            <title>Citokinske tarčne molekule za zdravljenje GCA</title>
            <p>Interlevkin (IL)-6. Vrednosti IL-6, glavnega sprožilca sinteze C-reaktivnega proteina (CRP) in serumskega amiloida A (SAA) so značilno povečane pri nezdravljenih bolnikih z GCA, prehodno se zmanjšajo po zdravljenju in so pogosto višje pri bolnikih s kronično boleznijo v primerjavi z zdravimi osebami (<xref ref-type="bibr" rid="b8">8</xref>). Statistično značilno višje vrednosti IL-6 pri bolnikih z GCA v primerjavi z zdravimi krvodajalci so bile dokazane z večimi metodami v več raziskavah (<xref ref-type="bibr" rid="b51">51</xref>-<xref ref-type="bibr" rid="b59">59</xref>). Prav tako so bile prisotne statistično pomembne višje vrednosti izražanja sporočilne ribonukleinske kisline (mRNK) IL-6 v biopsiji temporalne arterije bolnikov v primerjavi s kontrolami (<xref ref-type="bibr" rid="b52">52</xref>,<xref ref-type="bibr" rid="b60">60</xref>,<xref ref-type="bibr" rid="b61">61</xref>).</p>
            <p>Dasgupta B in Panayi GS (<xref ref-type="bibr" rid="b62">62</xref>) sta poročala, da se je aktivnost IL-6 povečala pri vseh bolnikih z nezdravljeno boleznijo. Pred 6 leti so zdravljenje z zaviralcem receptorja za IL-6 predlagali za zdravljenje GCA (<xref ref-type="bibr" rid="b63">63</xref>); po nekaj opisanih primerih hitro dosežene remisije (<xref ref-type="bibr" rid="b64">64</xref>). Leta 2013 so Unizony SH in sodelavci (<xref ref-type="bibr" rid="b25">25</xref>) objavili utemeljitev, zasnovo in načrt za največje klinično preizkušanje tocilizumaba (anti IL-6R) z vključenimi 250 bolniki. Postavili so hipotezo, da bi prekinjena signalna pot IL-6 lahko ugodno vplivala na izid GCA. Preliminarni rezultati o uporabi anti-IL-6 so spodbudni (<xref ref-type="bibr" rid="b65">65</xref>). Nedavna randomizirana, dvojno slepa in s placebom kontrolirana 2. faza raziskave je prvič pokazala učinkovitost tocilizumaba pri doseganju in vzdrževanju remisije (<xref ref-type="bibr" rid="b66">66</xref>). Ista skupina je ugotovila tudi 55-odstotno poslabšanje bolezni (mediani čas do poslabšanja je bil 5 mesecev) pri bolnikih po prenehanju zdravljenja s tocilizumabom. Pokazala je, da je tudi v primeru tocilizumaba potrebno za vzdrževanje remisije dolgoročno zdravljenje (<xref ref-type="bibr" rid="b67">67</xref>). Pred kratkim je skupina Stone in sodelavci poročala o oceni učinkovitosti in varnosti tocilizumaba pri bolnikih, ki so jemali zdravilo do 52 tednov v raziskavi GiACTA (randomizirana, dvojno slepa, s placebom kontrolirana raziskava) in ugotovila, da je tocilizumab v kombinaciji s 26-tedenskim zdravljenjem z GK bolj učinkovit v primerjavi z monoterapijo GK (<xref ref-type="bibr" rid="b68">68</xref>). Kljub temu je multicentrična retrospektivna študija tocilizumaba s 34 bolniki z GCA opozorila na neželene učinke, saj je 17 % bolnikov utrpelo hujše neželene učinke, kot so nevtropenija (3 bolniki), okužbe (1 bolnik je utrpel tuberkulozni perikarditis in 1 septični šok s smrtnim izidom) in jetrna ciroza (pri bolniku s sočasnim jemanjem MTX) (<xref ref-type="bibr" rid="b69">69</xref>).</p>
            <p>Antagonist receptorja IL-1. V raziskavi, ki je vključevala 3 bolnike z GCA, zdravljene z antagonistom receptorja IL-1 (anakinra), so ugotavljali izboljšanje simptomov bolezni in vnetnih kazalcev (<xref ref-type="bibr" rid="b70">70</xref>,<xref ref-type="bibr" rid="b71">71</xref>). Pomemben je tudi podatek, da so miši z izbitim genom IL-1Ra (knockout mice) razvile vaskulitis velikih žil (<xref ref-type="bibr" rid="b72">72</xref>). Za nadaljnje ovrednotenje zdravila so potrebne dodatne raziskave, saj ima antagonist IL-1 receptorja manj ugodne farmakokinetične značilnosti in je za njegovo učinkovitost potreben presežek nad endogenim IL-1 (<xref ref-type="bibr" rid="b70">70</xref>,<xref ref-type="bibr" rid="b71">71</xref>). Trenutno načrtujejo raziskavo z anakinro (Faza 3) GiAnT (US Clin trial.gov identifier NCT02902731), katere glavni namen je ugotoviti, ali lahko dodatek anakinre prepreči relaps.</p>
            <p>IL-1β. IL-1, ki izvira iz žilne stene, korelira s sistemskim vnetnim odzivom pri bolnikih z GCA. Dasgupta B je poročal o uporabi anti-IL1β in zapisal, da večina aktiviranih cirkulacijskih monocitov tvori IL-1 (<xref ref-type="bibr" rid="b72">72</xref>). Trenutno poteka klinično preizkušanje gevokizumaba (monoklonsko protitelo proti IL-1β) pri bolnikih z recidivno obliko GCA (European Clinical Trials Database identifier 2013–002778–38).</p>
            <p>IL-12/IL-23. Ustekinumab, monoklonsko protitelo proti IL-12/23p40, je učinkovit pri zdravljenju Crohnove bolezni in luskavice. Ker zavira celični odziv Th1 (IL-12, IFN-γ) in Th17 (IL-23, IL-1), bi lahko bil učinkovit tudi pri zdravljenju vaskulitisov velikih žil, kot je GCA. Conway R in sodelavci so poročali o raziskavi 14 bolnikov z neodzivno obliko GCA (<xref ref-type="bibr" rid="b34">34</xref>), ki je definirana kot neučinkovitost zniževanja GK (prednizolona) pod 10 mg/dan ali zaradi simptomov aktivne bolezni z vsaj 2 relapsoma (<xref ref-type="bibr" rid="b19">19</xref>). Ustekinumab je omogočil značilno znižanje odmerka GK in prenehanje jemanja drugih imunosupresivnih zdravil. Leta 2016 so Conway R in sodelavci nadalje objavili podatke o dolgoročni učinkovitosti ustekinumaba, ki je vodila v značilno znižanje odmerkov GK in proteinov akutne faze pri bolnikih z neodzivno obliko GCA (<xref ref-type="bibr" rid="b35">35</xref>).</p>
            <p>IL-17. Igral naj bi pomembno vlogo pri nastanku vnetja v žilni steni pri GCA. V biopsijah temporalne arterije bolnikov z GCA je bilo izmerjeno značilno povečano izražanje IL-17 z metodo kvantitativne verižne reakcije s polimerazo – QPCR (<xref ref-type="bibr" rid="b42">42</xref>,<xref ref-type="bibr" rid="b52">52</xref>,<xref ref-type="bibr" rid="b73">73</xref>,<xref ref-type="bibr" rid="b74">74</xref>). Poleg tega miši brez interferonskega regulacijskega proteina 4, ki inhibira IL-17A, razvijejo vaskulitis velikih žil (<xref ref-type="bibr" rid="b75">75</xref>). Marquez in sodelavci so leta 2014 objavili veliko metaanalizo, ki je vključila 1.266 z biopsijo potrjenih bolnikov GCA in 3.779 zdravih krvodajalcev iz 4 evropskih držav (Španija, Italija, Nemčija in Norveška). Poročali so o novi povezavi med polimorfizmi znotraj lokusa IL-17A in GCA (<xref ref-type="bibr" rid="b76">76</xref>). Iz perifernih levkocitov so osamili genomsko deoksiribonukleinsko kislino (DNK) in jo analizirali glede na 5 posameznih nukleotidnih polimorfizmov (<italic>angl.</italic> single nucleotide polymorphisms, SNPs) lociranih na lokusu IL-17A. Dokazali so 3 polimorfizme, ki predstavljajo tveganje za razvoj GCA. Presenetljivo so najmočnejšo povezavo našli z rs2275913, ki se nahaja na vezavnem mestu za transkripcijski jedrni faktor aktiviranih celic T (NFAT), ki je osrednji regulator promotorja IL-17 (<xref ref-type="bibr" rid="b76">76</xref>).</p>
            <p>Zaviranje IL-17 so preizkušali v več kliničnih raziskavah različnih avtoimunskih bolezni, v katerih so uporabljali različna biološka zdravila: sekukinumab, ixekizumab in brodalumab ter učinkovine ABT-122, RG4934, RG7624, SCH-900117 in SCH-900222 (imenovan tudi MK-3222). Dosegli so pozitivne in negativne rezultate in opisali kompleksnost pri napovedovanju bolnikovega odziva na zdravljenje, usmerjeno proti IL-17. Kljub nasprotujočim si rezultatom je jasno, da so cirkulacijske vrednosti IL-17A pri zdravih krvodajalcih in bolnikih z GCA zelo nizke (<xref ref-type="bibr" rid="b77">77</xref>). Vloga IL-17A kot tarčne molekule pri zdravljenju bolnikov z GCA trenutno ni jasna. Doslej še ni bila objavljena nobena raziskava z zaviralci IL-17 pri GCA.</p>
            <p>TNF-α. TNF-α je značilno povišan pri bolnikih z GCA, tako na proteinski (<xref ref-type="bibr" rid="b53">53</xref>,<xref ref-type="bibr" rid="b59">59</xref>,<xref ref-type="bibr" rid="b78">78</xref>) kot tudi na ravni mRNK (<xref ref-type="bibr" rid="b60">60</xref>,<xref ref-type="bibr" rid="b79">79</xref>) v serumu in biopsijah temporalne arterije. Kljub temu se ni izkazal za dobrega kandidata za zdravljenje. Raziskave z zaviralci TNF-α (infliximab, etanercept in adalimumab) niso uspele doseči ugodnih izidov zdravljenja GCA (<xref ref-type="bibr" rid="b80">80</xref>-<xref ref-type="bibr" rid="b82">82</xref>). Smernice združenja Evropske zveze za boj proti revmatizmu (EULAR) iz leta 2009 ne priporočajo njihove uporabe pri zdravljenju GCA.</p>
         </sec>
         <sec id="s4.2" sec-type="Druge necitokinske molekule">
            <label>4.2</label>
            <title>Druge necitokinske molekule</title>
            <p>Citotoksični s T-limfociti povezan protein 4 (CTLA-4) abatacept je fuzijski protein fragmenta IgG1 in zunajcelične domene CTLA-4. Veže se na CD80/86 na antigen predstavitvenih celicah in prepreči njihovo vezavo na CD28 celice T in njihovo aktiviranje. Langford in sodelavci (<xref ref-type="bibr" rid="b83">83</xref>) so pred kratkim zaključili multicentrično klinično raziskavo (Clinicaltrials.gov identifier: NCT00556439), v kateri so vsi bolniki prejeli indukcijsko zdravljenje z oralnim prednizolonom in infuzijo abatacepta 10 mg/kg v 1., 15., 29. dnevu in 8. teden zdravljenja GCA in arteritisa Takayasu. Preliminarni podatki za GCA so bili objavljeni v obliki povzetka (<xref ref-type="bibr" rid="b83">83</xref>). Iz njih je možno razbrati, da je bilo 41 bolnikov z GCA randomiziranih za proučevanje zdravila v 12. tednu (20 jih je prejelo abatacept, 21 placebo). Pri bolnikih, ki so bili zdravljeni z abataceptom, so ugotavljali značilno večji delež bolnikov, pri katerih do 12. meseca ni prišlo do poslabšanja bolezni (48 % proti 31 %) in daljši čas remisije (9,9 proti 3,9 meseca) v primerjavi s placebom. Rezultati so obetavni, vendar bodo v prihodnje potrebne potrditve na večji skupini bolnikov. Kritični pregled abatacepta in druga najnovejša dognanja pri zdravljenju GCA je pred kratkim opisal Koster MJ s sodelavci (<xref ref-type="bibr" rid="b84">84</xref>).</p>
            <p>CD20. GCA primarno velja za T-celično bolezen, kljub temu pa je prisotna tudi disregulacija celic B. (To je povzeto v (<xref ref-type="bibr" rid="b84">84</xref>)). Potencialno uporabo rituksimaba pri GCA so predlagali v 2 prikazih primera leta 2005 (<xref ref-type="bibr" rid="b85">85</xref>) in 2007 (<xref ref-type="bibr" rid="b86">86</xref>).</p>
            <p>Rho kinaza (ROCK). Izražanje mRNK ROCK je povečano v biopsijah temporalnih arterij bolnikov z GCA (<xref ref-type="bibr" rid="b87">87</xref>). Spremenjena aktivnost ROCK bi lahko igrala vlogo pri žilnem vnetju. V prihodnosti bo potrebno preučiti, kako zavirati aktivnost ROCK, in kakšno vlogo bi to imelo na fiziološke značilnosti imunskih celic, kot sta npr. signaliziranje in fagocitoza.</p>
            <p>Homolog proteina nevrogenega lokusa (NOTCH). Zaviranje NOTCH v humaniziranih mišjih modelih je pokazalo uspešno znižanje Th17 in izrazito zaviranje odziva Th1 ob zmanjšanju T-celičnih infiltratov v žilni spremembi (<xref ref-type="bibr" rid="b88">88</xref>). Motena signalna pot NOTCH močno zavira aktiviranje celic T v zgodnjih in poznih fazah žilnega vnetja. Modulacijo odziva NOTCH so predlagali kot eno novih strategij za imunosupresivno zdravljenje vaskulitisov velikih žil. Tako raziskava z ROCK kot tudi NOTCH receptorjem sta še vedno v predkliničnih stadijih in sta zaenkrat le potencialni tarči zdravljenja GCA.</p>
            <p>Zaviralec kinaze Janus (JAK). Klinična raziskava, ki bo ocenila varnost in učinkovitost baricitiniba (zaviralec JAK1 in JAK2) pri bolnikih z GCA še poteka (»Clinical trial identifier« NCT03026504).</p>
         </sec>
      </sec>
      <sec id="s5"
           sec-type="Klinično pomembna celična dinamika, vpletena v razvoj GCA – izbrane študije">
         <label>5</label>
         <title>Klinično pomembna celična dinamika, vpletena v razvoj GCA – izbrane študije</title>
         <p>Na celični ravni sta za imunopatologijo GCA pomembna predvsem Th1 (v kronični fazi bolezni) in Th17 (v zgodnji fazi bolezni) celični odziv (<xref ref-type="bibr" rid="b89">89</xref>). Pred kratkim je Fernandez-Fernandez FJ (<xref ref-type="bibr" rid="b90">90</xref>) kot dopolnilno zdravljenje pri GCA predlagal uporabo alfakalcidola, hormonskega pripravka vitamina D, ki ima v nasprotju z vitaminom D2 ali D3, <italic>in vitro</italic> ter <italic>in vivo</italic> imunomodulacijske učinke. Alfakalcidol bi lahko vplival na razmerje Treg/Th17 celic, kar je potrdila skupina Zold in sodelavci (<xref ref-type="bibr" rid="b91">91</xref>). Pokazali so, da 1 µg alfakalcidola na dan zmanjša koncentracije IL-6, IL-17, IL-12 in IFN-γ ter tudi delež cirkulacijskih celic Th1 in Th17, medtem ko poveča število cirkulacijskih celic Treg in povrne njihovo inhibicijsko vlogo. Vlogo alfakalcidola bi bilo smiselno preučiti bolj natančno pri zdravljenju GCA. Aktivna oblika vitamina D (1,25-dihidroksiholekalciferol) naj bi prav tako zmanjšala celični odziv Th1 in Th17 in spodbudila celice Treg v kombinaciji z IL-2 (<xref ref-type="bibr" rid="b92">92</xref>).</p>
         <p>Samson M in sodelavci (<xref ref-type="bibr" rid="b93">93</xref>) so prvič dokazali, da se število celic Treg pri bolnikih z GCA zmanjša in da so CD161+CD4+ limfociti T, diferencirani v Th1 in Th17 celice, vpleteni v patogenezo GCA. Med celicami Th1 in Th17 so bile ugotovljene temeljne razlike v njihovi odvisnosti od <italic>de novo</italic> sinteze maščobnih kislin, sprožene z acetil-coA karboksilazo 1, kar bi lahko izkoristili kot novo strategijo za presnovno imunsko modulacijo vnetnih bolezni, sproženih s celičnim odzivom Th17 (<xref ref-type="bibr" rid="b94">94</xref>). Cirkulacijske vrednosti celic T (CD8+) so bile znižane pri GCA, njihovo znižanje pa tudi korelira s stopnjo stenoze karotidne arterije (<xref ref-type="bibr" rid="b95">95</xref>,<xref ref-type="bibr" rid="b96">96</xref>). Samson M in sodelavci (<xref ref-type="bibr" rid="b97">97</xref>) so prav tako poročali o napovedni vlogi CD8+ celic T. Potencialno vlogo pri razvoju GCA naj bi zanimivo imeli tudi nevtrofilci, kar je leta 2014 poročala skupina Nadkarni S in sodelavci (<xref ref-type="bibr" rid="b98">98</xref>), ki opisuje obstoj povišanega vnetnega fenotipa med zniževanjem odmerka GK. Avtorji so opisali specifični nevtrofilni fenotip (značilno visoko izražanje CD62L in Annexin A1 [AnxA1]) ter nizko CD11b, ki se pojavi zgodaj v poteku bolezni ob zdravljenju z visokimi odmerki GK. Ob zniževanju odmerkov GK so opazili, da se pri določeni skupini bolnikov pojavi vnetni fenotip (nizek CD62L, visok CD11b, visok AnxA1), kar bi lahko napovedovalo neželene zaplete in relapse. Potrebno je poudariti, da je študija vključevala majhno število bolnikov in bo, za možnost ocenjevanja potencialne napovedne vloge tega nevtrofilnega fenotipa, potrebno večje število bolnikov. Poleg tega je ta študija predstavila zanimivo povezavo med nekaterimi prej omenjenimi citokini, saj je proučevala vrednosti IL-6 in IL-17 med zniževanjem odmerkov GK. Inkubacija zdravih nevtrofilnih granulocitov s patološkimi koncentracijami omenjenih citokinov (kot so prisotne pri GCA) promovira vnetni nevtrofilni fenotip, kar predstavlja možno vzročno povezavo med cirkulacijskimi in celičnimi mehanizmi, ki sodelujejo pri nastanku relapsirajoče bolezni in neželenih srčno-žilnih dogodkov.</p>
      </sec>
      <sec id="s6" sec-type="Zaključek">
         <label>6</label>
         <title>Zaključek</title>
         <p>Skrajševanje časovnega intervala med postavitvijo diagnoze in novimi terapevtskimi možnostmi bi lahko bolje preprečilo nastanek hudih zapletov pri bolnikih z GCA. Hitre, specializirane diagnostične ambulante za GCA so trenutno najučinkovitejši pristop k preprečevanju zapletov in boljšemu obvladovanju bolezni. Klinične raziskave novih možnosti zdravljenja so v teku, pri čemer trenutno največ obeta tocilizumab. Čeprav so novejši pristopi k zdravljenju usmerjeni bolj proti posameznim tarčnim molekulam, pa GCA “zahteva” širok pogled, saj je bolezen kompleksna, večvzročno pogojena in z motnjo na več ravneh celične in humoralne imunosti. Zato menimo, da bi poznavanje celične dinamike in določitev nevtrofilnih granulocitov in populacij celic T in B lahko prispevala k napovedovanju bolezenskega dogajanja, poslabšanj in bolnikovega odziva na zdravljenje.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Levin</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Ward</surname> 
                     <given-names>TN</given-names>
                  </name>
               </person-group>. <article-title>Horton’s disease: past and present</article-title>. <source>Curr Pain Headache Rep</source>. <year>2005</year> 
               <month>Aug</month>;<volume>9</volume>(<issue>4</issue>):<fpage>259</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1007/s11916-005-0033-4</pub-id>
               <pub-id pub-id-type="pmid">16004841</pub-id>
               <issn>1531-3433</issn>
               <annotation>
                  <p content-type="warning">Based on PubMed data, Edifix has added authors to this reference. The original author was "<underline>Levin</underline>". Please check carefully as this change may affect the in-text citations. (Ref. "Levin, Ward, 2005")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b2">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Watts</surname> 
                     <given-names>RA</given-names>
                  </name>, <name>
                     <surname>Suppiah</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Merkel</surname> 
                     <given-names>PA</given-names>
                  </name>, <name>
                     <surname>Luqmani</surname> 
                     <given-names>R</given-names>
                  </name>
               </person-group>. <article-title>Systemic vasculitis—is it time to reclassify?</article-title> 
               <source>Rheumatology (Oxford)</source>. <year>2011</year> 
               <month>Apr</month>;<volume>50</volume>(<issue>4</issue>):<fpage>643</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keq229</pub-id>
               <pub-id pub-id-type="pmid">20647295</pub-id>
               <issn>1462-0324</issn>
               <annotation>
                  <p content-type="warning">Based on PubMed data, Edifix has added authors to this reference. The original author was "<underline>Watts</underline>". Please check carefully as this change may affect the in-text citations. (Ref. "Watts, Suppiah, Merkel, Luqmani, 2011")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b3">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Borchers</surname> 
                     <given-names>AT</given-names>
                  </name>, <name>
                     <surname>Gershwin</surname> 
                     <given-names>ME</given-names>
                  </name>
               </person-group>. <article-title>Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment</article-title>. <source>Autoimmun Rev</source>. <year>2012</year> 
               <month>May</month>;<volume>11</volume>(<issue>6-7</issue>):<fpage>A544</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2012.01.003</pub-id>
               <pub-id pub-id-type="pmid">22285588</pub-id>
               <issn>1568-9972</issn>
            </mixed-citation>
         </ref>
         <ref id="b4">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Jennette</surname> 
                     <given-names>JC</given-names>
                  </name>, <name>
                     <surname>Falk</surname> 
                     <given-names>RJ</given-names>
                  </name>, <name>
                     <surname>Bacon</surname> 
                     <given-names>PA</given-names>
                  </name>, <name>
                     <surname>Basu</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Cid</surname> 
                     <given-names>MC</given-names>
                  </name>, <name>
                     <surname>Ferrario</surname> 
                     <given-names>F</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides</article-title>. <source>Arthritis Rheum</source>. <year>2013</year> 
               <month>Jan</month>;<volume>65</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/art.37715</pub-id>
               <pub-id pub-id-type="pmid">23045170</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b5">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ness</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Bley</surname> 
                     <given-names>TA</given-names>
                  </name>, <name>
                     <surname>Schmidt</surname> 
                     <given-names>WA</given-names>
                  </name>, <name>
                     <surname>Lamprecht</surname> 
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>The diagnosis and treatment of giant cell arteritis</article-title>. <source>Dtsch Arztebl Int</source>. <year>2013</year> 
               <month>May</month>;<volume>110</volume>(<issue>21</issue>):<fpage>376</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">23795218</pub-id>
               <issn>1866-0452</issn>
            </mixed-citation>
         </ref>
         <ref id="b6">
            <mixed-citation publication-type="book-chapter" specific-use="linked">
               <person-group person-group-type="author">
                  <name>
                     <surname>Nesher</surname> 
                     <given-names>G</given-names>
                  </name>
               </person-group>. <chapter-title>Giant cell arteritis.</chapter-title> In: (eds.) YSea, editor. Diagnostic Criteria in Autoimmune Diseases. Totowa NJ: Humana Press; <year>2008</year>. p. 73–6. <pub-id pub-id-type="doi">10.1007/978-1-60327-285-8_13</pub-id>
               <annotation>
                  <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. "Nesher, 2008")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b7">
            <mixed-citation publication-type="web-page" specific-use="unparsed">The Incidence Rate of Giant Cell Arteritis in Slovenia [Internet]. <year>2015</year> [cited August 11. 2016]. Available from: <ext-link ext-link-type="uri"
                         xlink:href="http://acrabstracts.org/abstract/the-incidence-rate-of-giant-cell-arteritis-in-slovenia/">http://acrabstracts.org/abstract/the-incidence-rate-of-giant-cell-arteritis-in-slovenia/</ext-link>
            </mixed-citation>
         </ref>
         <ref id="b8">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>, <name>
                     <surname>Goronzy</surname> 
                     <given-names>JJ</given-names>
                  </name>
               </person-group>. <article-title>Giant-cell arteritis and polymyalgia rheumatica</article-title>. <source>N Engl J Med</source>. <year>2014</year> 
               <month>Oct</month>;<volume>371</volume>(<issue>17</issue>):<fpage>1653</fpage>.<pub-id pub-id-type="pmid">25337759</pub-id>
               <issn>1533-4406</issn>
            </mixed-citation>
         </ref>
         <ref id="b9">
            <mixed-citation publication-type="unknown" specific-use="linked">
               <person-group person-group-type="author">
                  <name>
                     <surname>Dejaco</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Duftner</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Buttgereit</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Matteson</surname> 
                     <given-names>EL</given-names>
                  </name>, <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>
               </person-group>. <article-title>The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.</article-title> Rheumatology (Oxford). <year>2016</year>. <pub-id pub-id-type="doi">10.1093/rheumatology/kew273</pub-id>
            </mixed-citation>
         </ref>
         <ref id="b10">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Bienvenu</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Ly</surname> 
                     <given-names>KH</given-names>
                  </name>, <name>
                     <surname>Lambert</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Agard</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>André</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Benhamou</surname> 
                     <given-names>Y</given-names>
                  </name>, <etal>et al.</etal>; <collab>Groupe d’Étude Français des Artérites des gros Vaisseaux, under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares</collab>
               </person-group>. <article-title>Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)</article-title>. <source>Rev Med Interne</source>. <year>2016</year> 
               <month>Mar</month>;<volume>37</volume>(<issue>3</issue>):<fpage>154</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.revmed.2015.12.015</pub-id>
               <pub-id pub-id-type="pmid">26833145</pub-id>
               <issn>0248-8663</issn>
            </mixed-citation>
         </ref>
         <ref id="b11">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Liozon</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Ly</surname> 
                     <given-names>KH</given-names>
                  </name>, <name>
                     <surname>Robert</surname> 
                     <given-names>PY</given-names>
                  </name>
               </person-group>. <article-title>[Ocular complications of giant cell arteritis]</article-title>. <source>Rev Med Interne</source>. <year>2013</year> 
               <month>Jul</month>;<volume>34</volume>(<issue>7</issue>):<fpage>421</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.revmed.2013.02.030</pub-id>
               <pub-id pub-id-type="pmid">23523078</pub-id>
               <issn>0248-8663</issn>
               <annotation>
                  <p content-type="warning">PubMed reports the vernacular (French) article title is <underline>Manifestations ophtalmologiques de la maladie de Horton.</underline>. (Ref. "Liozon, Ly, Robert, 2013")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b12">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>González-Gay</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>García-Porrúa</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Llorca</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Hajeer</surname> 
                     <given-names>AH</given-names>
                  </name>, <name>
                     <surname>Brañas</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Dababneh</surname> 
                     <given-names>A</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients</article-title>. <source>Medicine (Baltimore)</source>. <year>2000</year> 
               <month>Sep</month>;<volume>79</volume>(<issue>5</issue>):<fpage>283</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1097/00005792-200009000-00001</pub-id>
               <pub-id pub-id-type="pmid">11039076</pub-id>
               <issn>0025-7974</issn>
            </mixed-citation>
         </ref>
         <ref id="b13">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>González-Gay</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>Blanco</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Rodríguez-Valverde</surname> 
                     <given-names>V</given-names>
                  </name>, <name>
                     <surname>Martínez-Taboada</surname> 
                     <given-names>VM</given-names>
                  </name>, <name>
                     <surname>Delgado-Rodriguez</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Figueroa</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment</article-title>. <source>Arthritis Rheum</source>. <year>1998</year> 
               <month>Aug</month>;<volume>41</volume>(<issue>8</issue>):<fpage>1497</fpage>–<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1002/1529-0131(199808)41:8&lt;1497::AID-ART22&gt;3.0.CO;2-Z</pub-id>
               <pub-id pub-id-type="pmid">9704651</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b14">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Salvarani</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Della Bella</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Cimino</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Macchioni</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Formisano</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Bajocchi</surname> 
                     <given-names>G</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2009</year> 
               <month>Mar</month>;<volume>48</volume>(<issue>3</issue>):<fpage>250</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/ken465</pub-id>
               <pub-id pub-id-type="pmid">19109317</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b15">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ninan</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Lester</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Hill</surname> 
                     <given-names>C</given-names>
                  </name>
               </person-group>. <article-title>Giant cell arteritis</article-title>. <source>Best Pract Res Clin Rheumatol</source>. <year>2016</year> 
               <month>Feb</month>;<volume>30</volume>(<issue>1</issue>):<fpage>169</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.berh.2016.05.001</pub-id>
               <pub-id pub-id-type="pmid">27421223</pub-id>
               <issn>1521-6942</issn>
            </mixed-citation>
         </ref>
         <ref id="b16">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Salvarani</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Gabriel</surname> 
                     <given-names>SE</given-names>
                  </name>, <name>
                     <surname>O’Fallon</surname> 
                     <given-names>WM</given-names>
                  </name>, <name>
                     <surname>Hunder</surname> 
                     <given-names>GG</given-names>
                  </name>
               </person-group>. <article-title>Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991</article-title>. <source>Arthritis Rheum</source>. <year>1995</year> 
               <month>Mar</month>;<volume>38</volume>(<issue>3</issue>):<fpage>369</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1002/art.1780380311</pub-id>
               <pub-id pub-id-type="pmid">7880191</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b17">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Gran</surname> 
                     <given-names>JT</given-names>
                  </name>, <name>
                     <surname>Myklebust</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Wilsgaard</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Jacobsen</surname> 
                     <given-names>BK</given-names>
                  </name>
               </person-group>. <article-title>Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls</article-title>. <source>Rheumatology (Oxford)</source>. <year>2001</year> 
               <month>Nov</month>;<volume>40</volume>(<issue>11</issue>):<fpage>1238</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/40.11.1238</pub-id>
               <pub-id pub-id-type="pmid">11709607</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b18">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Gonzalez-Gay</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>Barros</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Lopez-Diaz</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Garcia-Porrua</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Sanchez-Andrade</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Llorca</surname> 
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients</article-title>. <source>Medicine (Baltimore)</source>. <year>2005</year> 
               <month>Sep</month>;<volume>84</volume>(<issue>5</issue>):<fpage>269</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1097/01.md.0000180042.42156.d1</pub-id>
               <pub-id pub-id-type="pmid">16148727</pub-id>
               <issn>0025-7974</issn>
            </mixed-citation>
         </ref>
         <ref id="b19">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hunder</surname> 
                     <given-names>GG</given-names>
                  </name>, <name>
                     <surname>Bloch</surname> 
                     <given-names>DA</given-names>
                  </name>, <name>
                     <surname>Michel</surname> 
                     <given-names>BA</given-names>
                  </name>, <name>
                     <surname>Stevens</surname> 
                     <given-names>MB</given-names>
                  </name>, <name>
                     <surname>Arend</surname> 
                     <given-names>WP</given-names>
                  </name>, <name>
                     <surname>Calabrese</surname> 
                     <given-names>LH</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis</article-title>. <source>Arthritis Rheum</source>. <year>1990</year> 
               <month>Aug</month>;<volume>33</volume>(<issue>8</issue>):<fpage>1122</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/art.1780330810</pub-id>
               <pub-id pub-id-type="pmid">2202311</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b20">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Nesher</surname> 
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>The diagnosis and classification of giant cell arteritis</article-title>. <source>J Autoimmun</source>. <year>2014</year> 
               <month>Feb-Mar</month>;<volume>48-49</volume>:<fpage>73</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2014.01.017</pub-id>
               <pub-id pub-id-type="pmid">24461386</pub-id>
               <issn>0896-8411</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Nesher, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b21">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Luqmani</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Lee</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Singh</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Gillett</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Schmidt</surname> 
                     <given-names>WA</given-names>
                  </name>, <name>
                     <surname>Bradburn</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study</article-title>. <source>Health Technol Assess</source>. <year>2016</year> 
               <month>Nov</month>;<volume>20</volume>(<issue>90</issue>):<fpage>1</fpage>–<lpage>238</lpage>. <pub-id pub-id-type="doi">10.3310/hta20900</pub-id>
               <pub-id pub-id-type="pmid">27925577</pub-id>
               <issn>1366-5278</issn>
            </mixed-citation>
         </ref>
         <ref id="b22">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Schmidt</surname> 
                     <given-names>WA</given-names>
                  </name>
               </person-group>. <article-title>Role of ultrasound in the understanding and management of vasculitis</article-title>. <source>Ther Adv Musculoskelet Dis</source>. <year>2014</year> 
               <month>Apr</month>;<volume>6</volume>(<issue>2</issue>):<fpage>39</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1177/1759720X13512256</pub-id>
               <pub-id pub-id-type="pmid">24688604</pub-id>
               <issn>1759-720X</issn>
            </mixed-citation>
         </ref>
         <ref id="b23">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lee</surname> 
                     <given-names>YH</given-names>
                  </name>, <name>
                     <surname>Choi</surname> 
                     <given-names>SJ</given-names>
                  </name>, <name>
                     <surname>Ji</surname> 
                     <given-names>JD</given-names>
                  </name>, <name>
                     <surname>Song</surname> 
                     <given-names>GG</given-names>
                  </name>
               </person-group>. <article-title>Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis</article-title>. <source>Z Rheumatol</source>. <year>2016</year> 
               <month>Nov</month>;<volume>75</volume>(<issue>9</issue>):<fpage>924</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1007/s00393-015-1674-2</pub-id>
               <pub-id pub-id-type="pmid">26704559</pub-id>
               <issn>0340-1855</issn>
               <annotation>
                  <p content-type="warning">PubMed reports the vernacular (English) article title is <underline>Diagnostische Genauigkeit der 18F-FDG PET bzw. PET/CT für Vaskulitiden großer Gefäße : Eine Metaanalyse.</underline>. (Ref. "Lee, Choi, Ji, Song, 2016")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b24">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hocevar</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Rotar</surname> 
                     <given-names>Z</given-names>
                  </name>, <name>
                     <surname>Jese</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Semrl</surname> 
                     <given-names>SS</given-names>
                  </name>, <name>
                     <surname>Pizem</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Hawlina</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year> 
               <month>Apr</month>;<volume>95</volume>(<issue>14</issue>):<fpage>e3210</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000003210</pub-id>
               <pub-id pub-id-type="pmid">27057850</pub-id>
               <issn>0025-7974</issn>
            </mixed-citation>
         </ref>
         <ref id="b25">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Unizony</surname> 
                     <given-names>SH</given-names>
                  </name>, <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Fisheleva</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Rowell</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Schett</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Spiera</surname> 
                     <given-names>R</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Design of the tocilizumab in giant cell arteritis trial</article-title>. <source>Int J Rheumatol</source>. <year>2013</year>;<volume>2013</volume>:<fpage>912562</fpage>. <pub-id pub-id-type="doi">10.1155/2013/912562</pub-id>
               <pub-id pub-id-type="pmid">23653652</pub-id>
               <issn>1687-9260</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Unizony, Dasgupta, Fisheleva, Rowell, Schett, Spiera, et al., 2013")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b26">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Mukhtyar</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Guillevin</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Cid</surname> 
                     <given-names>MC</given-names>
                  </name>, <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>de Groot</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Gross</surname> 
                     <given-names>W</given-names>
                  </name>, <etal>et al.</etal>; <collab>European Vasculitis Study Group</collab>
               </person-group>. <article-title>EULAR recommendations for the management of large vessel vasculitis</article-title>. <source>Ann Rheum Dis</source>. <year>2009</year> 
               <month>Mar</month>;<volume>68</volume>(<issue>3</issue>):<fpage>318</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2008.088351</pub-id>
               <pub-id pub-id-type="pmid">18413441</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b27">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hoffman</surname> 
                     <given-names>GS</given-names>
                  </name>, <name>
                     <surname>Cid</surname> 
                     <given-names>MC</given-names>
                  </name>, <name>
                     <surname>Hellmann</surname> 
                     <given-names>DB</given-names>
                  </name>, <name>
                     <surname>Guillevin</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Stone</surname> 
                     <given-names>JH</given-names>
                  </name>, <name>
                     <surname>Schousboe</surname> 
                     <given-names>J</given-names>
                  </name>, <etal>et al.</etal>; <collab>International Network for the Study of Systemic Vasculitides</collab>
               </person-group>. <article-title>A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis</article-title>. <source>Arthritis Rheum</source>. <year>2002</year> 
               <month>May</month>;<volume>46</volume>(<issue>5</issue>):<fpage>1309</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1002/art.10262</pub-id>
               <pub-id pub-id-type="pmid">12115238</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b28">
            <mixed-citation publication-type="unknown" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Rodriguez Rodriguez</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Leon</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Morado</surname> 
                     <given-names>I</given-names>
                  </name>, <name>
                     <surname>Rosales Rosado</surname> 
                     <given-names>Z</given-names>
                  </name>, <name>
                     <surname>Vadillo Font</surname> 
                     <given-names>C</given-names>
                  </name>
               </person-group> FND, Macarrón P, et al. Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice [abstract]. Arthritis Rheumatol. <year>2016</year>;68 (suppl 10).</mixed-citation>
         </ref>
         <ref id="b29">
            <mixed-citation publication-type="unknown" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Koster</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Crowson</surname> 
                     <given-names>CS</given-names>
                  </name>, <name>
                     <surname>Labarca</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Muratore</surname> 
                     <given-names>F</given-names>
                  </name>
               </person-group>, KJ. W. Efficacy of Methotrexate in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. <year>2016</year>;68 (suppl 10).</mixed-citation>
         </ref>
         <ref id="b30">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Jover</surname> 
                     <given-names>JA</given-names>
                  </name>, <name>
                     <surname>Hernández-García</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Morado</surname> 
                     <given-names>IC</given-names>
                  </name>, <name>
                     <surname>Vargas</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Bañares</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Fernández-Gutiérrez</surname> 
                     <given-names>B</given-names>
                  </name>
               </person-group>. <article-title>Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial</article-title>. <source>Ann Intern Med</source>. <year>2001</year> 
               <month>Jan</month>;<volume>134</volume>(<issue>2</issue>):<fpage>106</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-134-2-200101160-00010</pub-id>
               <pub-id pub-id-type="pmid">11177313</pub-id>
               <issn>0003-4819</issn>
            </mixed-citation>
         </ref>
         <ref id="b31">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Diamantopoulos</surname> 
                     <given-names>AP</given-names>
                  </name>, <name>
                     <surname>Hetland</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Myklebust</surname> 
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series</article-title>. <source>BioMed Res Int</source>. <year>2013</year>;<volume>2013</volume>:<fpage>120638</fpage>. <pub-id pub-id-type="doi">10.1155/2013/120638</pub-id>
               <pub-id pub-id-type="pmid">24106691</pub-id>
               <issn>2314-6133</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Diamantopoulos, Hetland, Myklebust, 2013")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b32">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Voelker</surname> 
                     <given-names>R</given-names>
                  </name>
               </person-group>. <article-title>A First for Giant Cell Arteritis</article-title>. <source>JAMA</source>. <year>2017</year> 
               <month>Jul</month>;<volume>318</volume>(<issue>1</issue>):<fpage>20</fpage>.<pub-id pub-id-type="pmid">28672299</pub-id>
               <issn>1538-3598</issn>
            </mixed-citation>
         </ref>
         <ref id="b33">
            <mixed-citation publication-type="web-page" specific-use="unparsed">
               <person-group person-group-type="author">
                  <collab>FDA</collab>
               </person-group>. <article-title>FDA approves first drug to specifically treat giant cell arteritis</article-title> 
               <year>2017</year> [cited 2017 25 July 2017]. Available from: <ext-link ext-link-type="uri"
                         xlink:href="https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm559791.htm">https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm559791.htm</ext-link>
            </mixed-citation>
         </ref>
         <ref id="b34">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Conway</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>O’Neill</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>O’Flynn</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Gallagher</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>McCarthy</surname> 
                     <given-names>GM</given-names>
                  </name>, <name>
                     <surname>Murphy</surname> 
                     <given-names>CC</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Ustekinumab for the treatment of refractory giant cell arteritis</article-title>. <source>Ann Rheum Dis</source>. <year>2016</year> 
               <month>Aug</month>;<volume>75</volume>(<issue>8</issue>):<fpage>1578</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209351</pub-id>
               <pub-id pub-id-type="pmid">27143653</pub-id>
               <issn>0003-4967</issn>
               <annotation>
                  <p content-type="warning">Based on PubMed data, Edifix has added authors to this reference. The original author was "<underline>Conway</underline>". Please check carefully as this change may affect the in-text citations. (Ref. "Conway, O’Neill, O’Flynn, Gallagher, McCarthy, Murphy, et al., 2016")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b35">
            <mixed-citation publication-type="unknown" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Conway</surname> 
                     <given-names>R</given-names>
                  </name>
               </person-group>, O‘Neill L, Gallagher P, O‘Flynn E, McCarthy GM, Murphy C, et al. Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis [abstract]. Arthritis Rheumatol. <year>2016</year>;68 (suppl 10).</mixed-citation>
         </ref>
         <ref id="b36">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Diamantopoulos</surname> 
                     <given-names>AP</given-names>
                  </name>, <name>
                     <surname>Haugeberg</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Lindland</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Myklebust</surname> 
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?</article-title> 
               <source>Rheumatology (Oxford)</source>. <year>2016</year> 
               <month>Jan</month>;<volume>55</volume>(<issue>1</issue>):<fpage>66</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kev289</pub-id>
               <pub-id pub-id-type="pmid">26286743</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b37">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Carbonella</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Berardi</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Petricca</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Biscetti</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Alivernini</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Bosello</surname> 
                     <given-names>SL</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone</article-title>. <source>J Am Geriatr Soc</source>. <year>2016</year> 
               <month>Mar</month>;<volume>64</volume>(<issue>3</issue>):<fpage>672</fpage>–<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1111/jgs.14004</pub-id>
               <pub-id pub-id-type="pmid">27000356</pub-id>
               <issn>0002-8614</issn>
            </mixed-citation>
         </ref>
         <ref id="b38">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Seelinger</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Sznajd</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Judge</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Robson</surname> 
                     <given-names>JC</given-names>
                  </name>, <name>
                     <surname>Craven</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Jayne</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Predictors of Delay in Diagnosis of Giant Cell Arteritis and Antineutrophil Cytoplasm Antibody Associated Vasculitides: Analysis of Data from the Diagnostic &amp; Classification Criteria in Vasculitis Study</article-title>. <source>Rheumatology</source>. <year>2015</year>;<volume>•••</volume>:<fpage>i172</fpage>–<lpage>3</lpage>.<issn>0080-2727</issn>
               <annotation>
                  <p content-type="warning">The reference title appears to be set in title case rather than sentence case. (Ref. "Seelinger, Sznajd, Judge, Robson, Craven, Jayne, et al., 2015")</p>
                  <p content-type="warning">Please provide the missing volume number in this journal reference. (Ref. "Seelinger, Sznajd, Judge, Robson, Craven, Jayne, et al., 2015")</p>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Seelinger, Sznajd, Judge, Robson, Craven, Jayne, et al., 2015")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b39">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ezeonyeji</surname> 
                     <given-names>AN</given-names>
                  </name>, <name>
                     <surname>Borg</surname> 
                     <given-names>FA</given-names>
                  </name>, <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>
               </person-group>. <article-title>Delays in recognition and management of giant cell arteritis: results from a retrospective audit</article-title>. <source>Clin Rheumatol</source>. <year>2011</year> 
               <month>Feb</month>;<volume>30</volume>(<issue>2</issue>):<fpage>259</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-010-1616-y</pub-id>
               <pub-id pub-id-type="pmid">21086005</pub-id>
               <issn>0770-3198</issn>
            </mixed-citation>
         </ref>
         <ref id="b40">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Chandran</surname> 
                     <given-names>AK</given-names>
                  </name>, <name>
                     <surname>Udayakumar</surname> 
                     <given-names>PD</given-names>
                  </name>, <name>
                     <surname>Crowson</surname> 
                     <given-names>CS</given-names>
                  </name>, <name>
                     <surname>Warrington</surname> 
                     <given-names>KJ</given-names>
                  </name>, <name>
                     <surname>Matteson</surname> 
                     <given-names>EL</given-names>
                  </name>
               </person-group>. <article-title>The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009</article-title>. <source>Scand J Rheumatol</source>. <year>2015</year> 
               <month>May</month>;<volume>44</volume>(<issue>3</issue>):<fpage>215</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3109/03009742.2014.982701</pub-id>
               <pub-id pub-id-type="pmid">25606666</pub-id>
               <issn>0300-9742</issn>
            </mixed-citation>
         </ref>
         <ref id="b41">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Baldini</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Maugeri</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Ramirez</surname> 
                     <given-names>GA</given-names>
                  </name>, <name>
                     <surname>Giacomassi</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Castiglioni</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Prieto-González</surname> 
                     <given-names>S</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia</article-title>. <source>Arthritis Rheum</source>. <year>2012</year> 
               <month>Mar</month>;<volume>64</volume>(<issue>3</issue>):<fpage>854</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1002/art.33411</pub-id>
               <pub-id pub-id-type="pmid">21989653</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b42">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ciccia</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Rizzo</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Maugeri</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Alessandro</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Croci</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Guggino</surname> 
                     <given-names>G</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis</article-title>. <source>Ann Rheum Dis</source>. <year>2016</year>;<volume>•••</volume>: <pub-id pub-id-type="doi">10.1136/annrheumdis-2016–209217</pub-id>; [<comment>Epub ahead of print</comment>].<pub-id pub-id-type="pmid">27098405</pub-id>
               <issn>0003-4967</issn>
               <annotation>
                  <p content-type="warning">Edifix has not updated this reference because the year and volume differ from the author original and the first page is missing. The PubMed reference is <underline>Ciccia F, Rizzo A, Maugeri R, Alessandro R, Croci S, Guggino G, et al. Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis. 2017 Jan;76(1):235–43</underline>. (Ref. "Ciccia, Rizzo, Maugeri, Alessandro, Croci, Guggino, et al., 2016")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b43">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Labarca</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Koster</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Crowson</surname> 
                     <given-names>CS</given-names>
                  </name>, <name>
                     <surname>Makol</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Ytterberg</surname> 
                     <given-names>SR</given-names>
                  </name>, <name>
                     <surname>Matteson</surname> 
                     <given-names>EL</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study</article-title>. <source>Rheumatology (Oxford)</source>. <year>2016</year> 
               <month>Feb</month>;<volume>55</volume>(<issue>2</issue>):<fpage>347</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kev348</pub-id>
               <pub-id pub-id-type="pmid">26385368</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b44">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Muller</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Devilliers</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Besancenot</surname> 
                     <given-names>JF</given-names>
                  </name>, <name>
                     <surname>Manckoundia</surname> 
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Giant cell arteritis (Horton’s disease) in very elderly patients aged 80 years and older: A study of 25 cases</article-title>. <source>Geriatr Gerontol Int</source>. <year>2016</year> 
               <month>Jun</month>;<volume>16</volume>(<issue>6</issue>):<fpage>679</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1111/ggi.12536</pub-id>
               <pub-id pub-id-type="pmid">26081629</pub-id>
               <issn>1444-1586</issn>
            </mixed-citation>
         </ref>
         <ref id="b45">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Muratore</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Kermani</surname> 
                     <given-names>TA</given-names>
                  </name>, <name>
                     <surname>Crowson</surname> 
                     <given-names>CS</given-names>
                  </name>, <name>
                     <surname>Green</surname> 
                     <given-names>AB</given-names>
                  </name>, <name>
                     <surname>Salvarani</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Matteson</surname> 
                     <given-names>EL</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Large-vessel giant cell arteritis: a cohort study</article-title>. <source>Rheumatology (Oxford)</source>. <year>2015</year> 
               <month>Mar</month>;<volume>54</volume>(<issue>3</issue>):<fpage>463</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keu329</pub-id>
               <pub-id pub-id-type="pmid">25193809</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b46">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Alba</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>Mena-Madrazo</surname> 
                     <given-names>JA</given-names>
                  </name>, <name>
                     <surname>Reyes</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Flores-Suárez</surname> 
                     <given-names>LF</given-names>
                  </name>
               </person-group>. <article-title>Giant cell arteritis in Mexican patients</article-title>. <source>J Clin Rheumatol</source>. <year>2012</year> 
               <month>Jan</month>;<volume>18</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/RHU.0b013e31823e2e35</pub-id>
               <pub-id pub-id-type="pmid">22157266</pub-id>
               <issn>1076-1608</issn>
            </mixed-citation>
         </ref>
         <ref id="b47">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Alba</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>García-Martínez</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Prieto-González</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Tavera-Bahillo</surname> 
                     <given-names>I</given-names>
                  </name>, <name>
                     <surname>Corbera-Bellalta</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Planas-Rigol</surname> 
                     <given-names>E</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients</article-title>. <source>Medicine (Baltimore)</source>. <year>2014</year> 
               <month>Jul</month>;<volume>93</volume>(<issue>5</issue>):<fpage>194</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000000033</pub-id>
               <pub-id pub-id-type="pmid">25181312</pub-id>
               <issn>0025-7974</issn>
            </mixed-citation>
         </ref>
         <ref id="b48">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Singh</surname> 
                     <given-names>AG</given-names>
                  </name>, <name>
                     <surname>Kermani</surname> 
                     <given-names>TA</given-names>
                  </name>, <name>
                     <surname>Crowson</surname> 
                     <given-names>CS</given-names>
                  </name>, <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>, <name>
                     <surname>Matteson</surname> 
                     <given-names>EL</given-names>
                  </name>, <name>
                     <surname>Warrington</surname> 
                     <given-names>KJ</given-names>
                  </name>
               </person-group>. <article-title>Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort</article-title>. <source>J Rheumatol</source>. <year>2015</year> 
               <month>Feb</month>;<volume>42</volume>(<issue>2</issue>):<fpage>309</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.3899/jrheum.140188</pub-id>
               <pub-id pub-id-type="pmid">25512481</pub-id>
               <issn>0315-162X</issn>
            </mixed-citation>
         </ref>
         <ref id="b49">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Gonzalez-Gay</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>Miranda-Filloy</surname> 
                     <given-names>JA</given-names>
                  </name>, <name>
                     <surname>Lopez-Diaz</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Perez-Alvarez</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Gonzalez-Juanatey</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Sanchez-Andrade</surname> 
                     <given-names>A</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study</article-title>. <source>Medicine (Baltimore)</source>. <year>2007</year> 
               <month>Mar</month>;<volume>86</volume>(<issue>2</issue>):<fpage>61</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/md.0b013e31803d1764</pub-id>
               <pub-id pub-id-type="pmid">17435586</pub-id>
               <issn>0025-7974</issn>
            </mixed-citation>
         </ref>
         <ref id="b50">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Gonzalez-Gay</surname> 
                     <given-names>MA</given-names>
                  </name>, <name>
                     <surname>Castañeda</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Llorca</surname> 
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Giant Cell Arteritis: Visual Loss Is Our Major Concern</article-title>. <source>J Rheumatol</source>. <year>2016</year> 
               <month>Aug</month>;<volume>43</volume>(<issue>8</issue>):<fpage>1458</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.3899/jrheum.160466</pub-id>
               <pub-id pub-id-type="pmid">27481989</pub-id>
               <issn>0315-162X</issn>
            </mixed-citation>
         </ref>
         <ref id="b51">
            <mixed-citation publication-type="conference" specific-use="unparsed">
               <person-group person-group-type="editor">
                  <name>
                     <surname>Žigon</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Lakota</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Kuret</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Tomšič</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Čučnik</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Sodin-Šemrl</surname> 
                     <given-names>S</given-names>
                  </name>, <etal>et al.</etal>, <role>editors</role>
               </person-group>. Acute Phase Proteins and Interleukin-6 are Important in Distinguishing between Giant Cell Arteritis Positive and Negative Patients. 10th international congress on autoimmunity; <year>2016</year>; Leipzig: Autoimmunity.</mixed-citation>
         </ref>
         <ref id="b52">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Deng</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Younge</surname> 
                     <given-names>BR</given-names>
                  </name>, <name>
                     <surname>Olshen</surname> 
                     <given-names>RA</given-names>
                  </name>, <name>
                     <surname>Goronzy</surname> 
                     <given-names>JJ</given-names>
                  </name>, <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>
               </person-group>. <article-title>Th17 and Th1 T-cell responses in giant cell arteritis</article-title>. <source>Circulation</source>. <year>2010</year> 
               <month>Feb</month>;<volume>121</volume>(<issue>7</issue>):<fpage>906</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.872903</pub-id>
               <pub-id pub-id-type="pmid">20142449</pub-id>
               <issn>0009-7322</issn>
            </mixed-citation>
         </ref>
         <ref id="b53">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hernández-Rodríguez</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>García-Martínez</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Casademont</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Filella</surname> 
                     <given-names>X</given-names>
                  </name>, <name>
                     <surname>Esteban</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>López-Soto</surname> 
                     <given-names>A</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis</article-title>. <source>Arthritis Rheum</source>. <year>2002</year> 
               <month>Feb</month>;<volume>47</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/art1.10161</pub-id>
               <pub-id pub-id-type="pmid">11932875</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b54">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Roblot</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Morel</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Lelievre</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Gascan</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Wijdenes</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Lecron</surname> 
                     <given-names>JC</given-names>
                  </name>
               </person-group>. <article-title>Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy</article-title>. <source>J Rheumatol</source>. <year>1996</year> 
               <month>Feb</month>;<volume>23</volume>(<issue>2</issue>):<fpage>408</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">8882065</pub-id>
               <issn>0315-162X</issn>
            </mixed-citation>
         </ref>
         <ref id="b55">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Emilie</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Liozon</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Crevon</surname> 
                     <given-names>MC</given-names>
                  </name>, <name>
                     <surname>Lavignac</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Portier</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Liozon</surname> 
                     <given-names>F</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Production of interleukin 6 by granulomas of giant cell arteritis</article-title>. <source>Hum Immunol</source>. <year>1994</year> 
               <month>Jan</month>;<volume>39</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/0198-8859(94)90096-5</pub-id>
               <pub-id pub-id-type="pmid">8181959</pub-id>
               <issn>0198-8859</issn>
            </mixed-citation>
         </ref>
         <ref id="b56">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lecron</surname> 
                     <given-names>JC</given-names>
                  </name>, <name>
                     <surname>Roblot</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Chevalier</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Morel</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Alderman</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Gombert</surname> 
                     <given-names>J</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>High circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapy</article-title>. <source>Clin Exp Immunol</source>. <year>1993</year> 
               <month>Apr</month>;<volume>92</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.1993.tb05942.x</pub-id>
               <pub-id pub-id-type="pmid">8096803</pub-id>
               <issn>0009-9104</issn>
            </mixed-citation>
         </ref>
         <ref id="b57">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Roche</surname> 
                     <given-names>NE</given-names>
                  </name>, <name>
                     <surname>Fulbright</surname> 
                     <given-names>JW</given-names>
                  </name>, <name>
                     <surname>Wagner</surname> 
                     <given-names>AD</given-names>
                  </name>, <name>
                     <surname>Hunder</surname> 
                     <given-names>GG</given-names>
                  </name>, <name>
                     <surname>Goronzy</surname> 
                     <given-names>JJ</given-names>
                  </name>, <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>
               </person-group>. <article-title>Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis</article-title>. <source>Arthritis Rheum</source>. <year>1993</year> 
               <month>Sep</month>;<volume>36</volume>(<issue>9</issue>):<fpage>1286</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1002/art.1780360913</pub-id>
               <pub-id pub-id-type="pmid">8216422</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b58">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>van der Geest</surname> 
                     <given-names>KS</given-names>
                  </name>, <name>
                     <surname>Abdulahad</surname> 
                     <given-names>WH</given-names>
                  </name>, <name>
                     <surname>Rutgers</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Horst</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Bijzet</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Arends</surname> 
                     <given-names>S</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica</article-title>. <source>Rheumatology (Oxford)</source>. <year>2015</year> 
               <month>Aug</month>;<volume>54</volume>(<issue>8</issue>):<fpage>1397</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keu526</pub-id>
               <pub-id pub-id-type="pmid">25724206</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b59">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Terrier</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Geri</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Chaara</surname> 
                     <given-names>W</given-names>
                  </name>, <name>
                     <surname>Allenbach</surname> 
                     <given-names>Y</given-names>
                  </name>, <name>
                     <surname>Rosenzwajg</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Costedoat-Chalumeau</surname> 
                     <given-names>N</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis</article-title>. <source>Arthritis Rheum</source>. <year>2012</year> 
               <month>Jun</month>;<volume>64</volume>(<issue>6</issue>):<fpage>2001</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1002/art.34327</pub-id>
               <pub-id pub-id-type="pmid">22147555</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b60">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ciccia</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Alessandro</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Rizzo</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Principe</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Raiata</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Cavazza</surname> 
                     <given-names>A</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis</article-title>. <source>Arthritis Rheum</source>. <year>2011</year> 
               <month>Jul</month>;<volume>63</volume>(<issue>7</issue>):<fpage>2097</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1002/art.30374</pub-id>
               <pub-id pub-id-type="pmid">21452292</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b61">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>, <name>
                     <surname>Hicok</surname> 
                     <given-names>KC</given-names>
                  </name>, <name>
                     <surname>Hunder</surname> 
                     <given-names>GG</given-names>
                  </name>, <name>
                     <surname>Goronzy</surname> 
                     <given-names>JJ</given-names>
                  </name>
               </person-group>. <article-title>Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis</article-title>. <source>Ann Intern Med</source>. <year>1994</year> 
               <month>Oct</month>;<volume>121</volume>(<issue>7</issue>):<fpage>484</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-121-7-199410010-00003</pub-id>
               <pub-id pub-id-type="pmid">8067646</pub-id>
               <issn>0003-4819</issn>
            </mixed-citation>
         </ref>
         <ref id="b62">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Panayi</surname> 
                     <given-names>GS</given-names>
                  </name>
               </person-group>. <article-title>Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis</article-title>. <source>Br J Rheumatol</source>. <year>1990</year> 
               <month>Dec</month>;<volume>29</volume>(<issue>6</issue>):<fpage>456</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/29.6.456</pub-id>
               <pub-id pub-id-type="pmid">2124160</pub-id>
               <issn>0263-7103</issn>
            </mixed-citation>
         </ref>
         <ref id="b63">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Beyer</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Axmann</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Sahinbegovic</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Distler</surname> 
                     <given-names>JH</given-names>
                  </name>, <name>
                     <surname>Manger</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Schett</surname> 
                     <given-names>G</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis</article-title>. <source>Ann Rheum Dis</source>. <year>2011</year> 
               <month>Oct</month>;<volume>70</volume>(<issue>10</issue>):<fpage>1874</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2010.149351</pub-id>
               <pub-id pub-id-type="pmid">21515917</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b64">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Seitz</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Reichenbach</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Bonel</surname> 
                     <given-names>HM</given-names>
                  </name>, <name>
                     <surname>Adler</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Wermelinger</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Villiger</surname> 
                     <given-names>PM</given-names>
                  </name>
               </person-group>. <article-title>Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series</article-title>. <source>Swiss Med Wkly</source>. <year>2011</year> 
               <month>Jan</month>;<volume>141</volume>:<fpage>w13156</fpage>.<pub-id pub-id-type="pmid">21243547</pub-id>
               <issn>1424-3997</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Seitz, Reichenbach, Bonel, Adler, Wermelinger, Villiger, 2011")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b65">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ferfar</surname> 
                     <given-names>Y</given-names>
                  </name>, <name>
                     <surname>Mirault</surname> 
                     <given-names>T</given-names>
                  </name>, <name>
                     <surname>Desbois</surname> 
                     <given-names>AC</given-names>
                  </name>, <name>
                     <surname>Comarmond</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Messas</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Savey</surname> 
                     <given-names>L</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Biotherapies in large vessel vasculitis</article-title>. <source>Autoimmun Rev</source>. <year>2016</year> 
               <month>Jun</month>;<volume>15</volume>(<issue>6</issue>):<fpage>544</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2016.02.012</pub-id>
               <pub-id pub-id-type="pmid">26883459</pub-id>
               <issn>1568-9972</issn>
            </mixed-citation>
         </ref>
         <ref id="b66">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Villiger</surname> 
                     <given-names>PM</given-names>
                  </name>, <name>
                     <surname>Adler</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Kuchen</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Wermelinger</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Dan</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Fiege</surname> 
                     <given-names>V</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2016</year> 
               <month>May</month>;<volume>387</volume>(<issue>10031</issue>):<fpage>1921</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00560-2</pub-id>
               <pub-id pub-id-type="pmid">26952547</pub-id>
               <issn>0140-6736</issn>
            </mixed-citation>
         </ref>
         <ref id="b67">
            <mixed-citation publication-type="unknown" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Adler</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Reichenbach</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Kuchen</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Wermelinger</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Dan</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Seitz</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137) [abstract]. Arthritis Rheumatol. <year>2016</year>;68 (suppl 10).</mixed-citation>
         </ref>
         <ref id="b68">
            <mixed-citation publication-type="unknown" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Stone</surname> 
                     <given-names>JH</given-names>
                  </name>, <name>
                     <surname>Tuckwell</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Dimonaco</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Klearman</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Aringer</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Blockmans</surname> 
                     <given-names>D</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. <year>2016</year>;68 (suppl 10).</mixed-citation>
         </ref>
         <ref id="b69">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Régent</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Redeker</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Deroux</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Kieffer</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Ly</surname> 
                     <given-names>KH</given-names>
                  </name>, <name>
                     <surname>Dougados</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al.</etal>; <collab>French Vasculitis Group, the Groupe Francais pour l’Etude de l’Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation</collab>
               </person-group>. <article-title>Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients</article-title>. <source>J Rheumatol</source>. <year>2016</year> 
               <month>Aug</month>;<volume>43</volume>(<issue>8</issue>):<fpage>1547</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.3899/jrheum.151252</pub-id>
               <pub-id pub-id-type="pmid">27182063</pub-id>
               <issn>0315-162X</issn>
            </mixed-citation>
         </ref>
         <ref id="b70">
            <mixed-citation publication-type="book-chapter" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Dejaco</surname> 
                     <given-names>C</given-names>
                  </name>
               </person-group>. <chapter-title>Role of steroid-sparing agents</chapter-title>. In: <person-group person-group-type="editor">
                  <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Dejaco</surname> 
                     <given-names>C</given-names>
                  </name>, <role>editors</role>
               </person-group>. <source>Polymyalgia Rheumatica and Giant Cell Arteritis</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2016</year>. pp. <fpage>89</fpage>–<lpage>95</lpage>.</mixed-citation>
         </ref>
         <ref id="b71">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ly</surname> 
                     <given-names>KH</given-names>
                  </name>, <name>
                     <surname>Stirnemann</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Liozon</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Michel</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Fain</surname> 
                     <given-names>O</given-names>
                  </name>, <name>
                     <surname>Fauchais</surname> 
                     <given-names>AL</given-names>
                  </name>
               </person-group>. <article-title>Interleukin-1 blockade in refractory giant cell arteritis</article-title>. <source>Joint Bone Spine</source>. <year>2014</year> 
               <month>Jan</month>;<volume>81</volume>(<issue>1</issue>):<fpage>76</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbspin.2013.06.004</pub-id>
               <pub-id pub-id-type="pmid">23890680</pub-id>
               <issn>1297-319X</issn>
            </mixed-citation>
         </ref>
         <ref id="b72">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>
               </person-group>. <article-title>A randomised, double-blinded, placebo controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. Second International Symposium and Imaging Workshop Giant Cell Arteritis, Polymyalgia Rheumatica and Large Vessel Vasculitis</article-title>. <source>Rheumatology</source>. <year>2014</year>;<volume>53</volume> 
               <supplement>suppl.2</supplement>:<fpage>i7</fpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keu197</pub-id>
               <issn>0080-2727</issn>
               <annotation>
                  <p content-type="warning">Edifix has not updated this reference because the article title in Crossref significantly differs from the author's original. The Crossref reference is <underline>Dasgupta B. 12. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. Rheumatology. 2014 Jul;53 suppl 2:i7</underline>. (Ref. "Dasgupta, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b73">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Espígol-Frigolé</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Corbera-Bellalta</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Planas-Rigol</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Lozano</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Segarra</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>García-Martínez</surname> 
                     <given-names>A</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis</article-title>. <source>Ann Rheum Dis</source>. <year>2013</year> 
               <month>Sep</month>;<volume>72</volume>(<issue>9</issue>):<fpage>1481</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201836</pub-id>
               <pub-id pub-id-type="pmid">22993227</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b74">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Ciccia</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Rizzo</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Guggino</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Cavazza</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Alessandro</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Maugeri</surname> 
                     <given-names>R</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2015</year> 
               <month>Sep</month>;<volume>54</volume>(<issue>9</issue>):<fpage>1596</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kev102</pub-id>
               <pub-id pub-id-type="pmid">25862016</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b75">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Chen</surname> 
                     <given-names>Q</given-names>
                  </name>, <name>
                     <surname>Yang</surname> 
                     <given-names>W</given-names>
                  </name>, <name>
                     <surname>Gupta</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Biswas</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Smith</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Bhagat</surname> 
                     <given-names>G</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor</article-title>. <source>Immunity</source>. <year>2008</year> 
               <month>Dec</month>;<volume>29</volume>(<issue>6</issue>):<fpage>899</fpage>–<lpage>911</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2008.10.011</pub-id>
               <pub-id pub-id-type="pmid">19062315</pub-id>
               <issn>1074-7613</issn>
            </mixed-citation>
         </ref>
         <ref id="b76">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Márquez</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Hernández-Rodríguez</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Cid</surname> 
                     <given-names>MC</given-names>
                  </name>, <name>
                     <surname>Solans</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Castañeda</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Fernández-Contreras</surname> 
                     <given-names>ME</given-names>
                  </name>, <etal>et al.</etal>; <collab>Spanish GCA Consortium</collab>
               </person-group>. <article-title>Influence of the IL17A locus in giant cell arteritis susceptibility</article-title>. <source>Ann Rheum Dis</source>. <year>2014</year> 
               <month>Sep</month>;<volume>73</volume>(<issue>9</issue>):<fpage>1742</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2014-205261</pub-id>
               <pub-id pub-id-type="pmid">24919468</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b77">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Miossec</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Kolls</surname> 
                     <given-names>JK</given-names>
                  </name>
               </person-group>. <article-title>Targeting IL-17 and TH17 cells in chronic inflammation</article-title>. <source>Nat Rev Drug Discov</source>. <year>2012</year> 
               <month>Oct</month>;<volume>11</volume>(<issue>10</issue>):<fpage>763</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3794</pub-id>
               <pub-id pub-id-type="pmid">23023676</pub-id>
               <issn>1474-1776</issn>
            </mixed-citation>
         </ref>
         <ref id="b78">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Blain</surname> 
                     <given-names>H</given-names>
                  </name>, <name>
                     <surname>Abdelmouttaleb</surname> 
                     <given-names>I</given-names>
                  </name>, <name>
                     <surname>Belmin</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Blain</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Floquet</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Guéant</surname> 
                     <given-names>JL</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Arterial wall production of cytokines in giant cell arteritis: results of a pilot study using human temporal artery cultures</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2002</year> 
               <month>Apr</month>;<volume>57</volume>(<issue>4</issue>):<fpage>M241</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/gerona/57.4.M241</pub-id>
               <pub-id pub-id-type="pmid">11909890</pub-id>
               <issn>1079-5006</issn>
            </mixed-citation>
         </ref>
         <ref id="b79">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hernández-Rodríguez</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Segarra</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Vilardell</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Sánchez</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>García-Martínez</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Esteban</surname> 
                     <given-names>MJ</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2004</year> 
               <month>Mar</month>;<volume>43</volume>(<issue>3</issue>):<fpage>294</fpage>–<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keh058</pub-id>
               <pub-id pub-id-type="pmid">14679293</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b80">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Hoffman</surname> 
                     <given-names>GS</given-names>
                  </name>, <name>
                     <surname>Cid</surname> 
                     <given-names>MC</given-names>
                  </name>, <name>
                     <surname>Rendt-Zagar</surname> 
                     <given-names>KE</given-names>
                  </name>, <name>
                     <surname>Merkel</surname> 
                     <given-names>PA</given-names>
                  </name>, <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>, <name>
                     <surname>Stone</surname> 
                     <given-names>JH</given-names>
                  </name>, <etal>et al.</etal>; <collab>Infliximab-GCA Study Group</collab>
               </person-group>. <article-title>Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial</article-title>. <source>Ann Intern Med</source>. <year>2007</year> 
               <month>May</month>;<volume>146</volume>(<issue>9</issue>):<fpage>621</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-146-9-200705010-00004</pub-id>
               <pub-id pub-id-type="pmid">17470830</pub-id>
               <issn>0003-4819</issn>
            </mixed-citation>
         </ref>
         <ref id="b81">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Martínez-Taboada</surname> 
                     <given-names>VM</given-names>
                  </name>, <name>
                     <surname>Rodríguez-Valverde</surname> 
                     <given-names>V</given-names>
                  </name>, <name>
                     <surname>Carreño</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>López-Longo</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Figueroa</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Belzunegui</surname> 
                     <given-names>J</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects</article-title>. <source>Ann Rheum Dis</source>. <year>2008</year> 
               <month>May</month>;<volume>67</volume>(<issue>5</issue>):<fpage>625</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2007.082115</pub-id>
               <pub-id pub-id-type="pmid">18086726</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b82">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Seror</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Baron</surname> 
                     <given-names>G</given-names>
                  </name>, <name>
                     <surname>Hachulla</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Debandt</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Larroche</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Puéchal</surname> 
                     <given-names>X</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial</article-title>. <source>Ann Rheum Dis</source>. <year>2014</year> 
               <month>Dec</month>;<volume>73</volume>(<issue>12</issue>):<fpage>2074</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203586</pub-id>
               <pub-id pub-id-type="pmid">23897775</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b83">
            <mixed-citation publication-type="conference" specific-use="unparsed">
               <person-group person-group-type="author">
                  <name>
                     <surname>Langford</surname> 
                     <given-names>CA</given-names>
                  </name>, <name>
                     <surname>Cuthbertson</surname> 
                     <given-names>D</given-names>
                  </name>, <name>
                     <surname>Ytterberg</surname> 
                     <given-names>SR</given-names>
                  </name>, <name>
                     <surname>Khalidi</surname> 
                     <given-names>NA</given-names>
                  </name>, <name>
                     <surname>Monach</surname> 
                     <given-names>PA</given-names>
                  </name>
               </person-group>. <article-title>Carette, et al. A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis.</article-title> 
               <source>2015 ACR/ARHP Annual Meeting: Arthritis Rheumatol</source>.; <year>2015</year>;67(suppl.10).</mixed-citation>
         </ref>
         <ref id="b84">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Koster</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Matteson</surname> 
                     <given-names>EL</given-names>
                  </name>, <name>
                     <surname>Warrington</surname> 
                     <given-names>KJ</given-names>
                  </name>
               </person-group>. <article-title>Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis</article-title>. <source>Curr Opin Rheumatol</source>. <year>2016</year> 
               <month>May</month>;<volume>28</volume>(<issue>3</issue>):<fpage>211</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/BOR.0000000000000265</pub-id>
               <pub-id pub-id-type="pmid">26885650</pub-id>
               <issn>1040-8711</issn>
            </mixed-citation>
         </ref>
         <ref id="b85">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Bhatia</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Ell</surname> 
                     <given-names>PJ</given-names>
                  </name>, <name>
                     <surname>Edwards</surname> 
                     <given-names>JC</given-names>
                  </name>
               </person-group>. <article-title>Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis</article-title>. <source>Ann Rheum Dis</source>. <year>2005</year> 
               <month>Jul</month>;<volume>64</volume>(<issue>7</issue>):<fpage>1099</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2005.036533</pub-id>
               <pub-id pub-id-type="pmid">15958774</pub-id>
               <issn>0003-4967</issn>
            </mixed-citation>
         </ref>
         <ref id="b86">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Mayrbaeurl</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Hinterreiter</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Burgstaller</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Windpessl</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Thaler</surname> 
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab</article-title>. <source>Clin Rheumatol</source>. <year>2007</year> 
               <month>Sep</month>;<volume>26</volume>(<issue>9</issue>):<fpage>1597</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-007-0684-0</pub-id>
               <pub-id pub-id-type="pmid">17619810</pub-id>
               <issn>0770-3198</issn>
            </mixed-citation>
         </ref>
         <ref id="b87">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Lally</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Pernis</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Narula</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Huang</surname> 
                     <given-names>WT</given-names>
                  </name>, <name>
                     <surname>Spiera</surname> 
                     <given-names>R</given-names>
                  </name>
               </person-group>. <article-title>Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2015</year> 
               <month>Mar</month>;<volume>54</volume>(<issue>3</issue>):<fpage>554</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/keu364</pub-id>
               <pub-id pub-id-type="pmid">25213129</pub-id>
               <issn>1462-0324</issn>
            </mixed-citation>
         </ref>
         <ref id="b88">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Piggott</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Deng</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Warrington</surname> 
                     <given-names>K</given-names>
                  </name>, <name>
                     <surname>Younge</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Kubo</surname> 
                     <given-names>JT</given-names>
                  </name>, <name>
                     <surname>Desai</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis</article-title>. <source>Circulation</source>. <year>2011</year> 
               <month>Jan</month>;<volume>123</volume>(<issue>3</issue>):<fpage>309</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.936203</pub-id>
               <pub-id pub-id-type="pmid">21220737</pub-id>
               <issn>0009-7322</issn>
            </mixed-citation>
         </ref>
         <ref id="b89">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Weyand</surname> 
                     <given-names>CM</given-names>
                  </name>, <name>
                     <surname>Goronzy</surname> 
                     <given-names>JJ</given-names>
                  </name>
               </person-group>. <article-title>Immune mechanisms in medium and large-vessel vasculitis</article-title>. <source>Nat Rev Rheumatol</source>. <year>2013</year> 
               <month>Dec</month>;<volume>9</volume>(<issue>12</issue>):<fpage>731</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2013.161</pub-id>
               <pub-id pub-id-type="pmid">24189842</pub-id>
               <issn>1759-4790</issn>
            </mixed-citation>
         </ref>
         <ref id="b90">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Fernández-Fernández</surname> 
                     <given-names>FJ</given-names>
                  </name>
               </person-group>. <article-title>Treg cells in giant cell arteritis: might they be another target for adjuvant treatment? Comment on the article by Samson et al</article-title>. <source>Arthritis Rheum</source>. <year>2013</year> 
               <month>Jan</month>;<volume>65</volume>(<issue>1</issue>):<fpage>289</fpage>. <pub-id pub-id-type="doi">10.1002/art.37700</pub-id>
               <pub-id pub-id-type="pmid">23001860</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b91">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Zold</surname> 
                     <given-names>E</given-names>
                  </name>, <name>
                     <surname>Szodoray</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Nakken</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Barath</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Kappelmayer</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Csathy</surname> 
                     <given-names>L</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease</article-title>. <source>Autoimmun Rev</source>. <year>2011</year> 
               <month>Jan</month>;<volume>10</volume>(<issue>3</issue>):<fpage>155</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2010.09.018</pub-id>
               <pub-id pub-id-type="pmid">20868777</pub-id>
               <issn>1568-9972</issn>
            </mixed-citation>
         </ref>
         <ref id="b92">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Jeffery</surname> 
                     <given-names>LE</given-names>
                  </name>, <name>
                     <surname>Burke</surname> 
                     <given-names>F</given-names>
                  </name>, <name>
                     <surname>Mura</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Zheng</surname> 
                     <given-names>Y</given-names>
                  </name>, <name>
                     <surname>Qureshi</surname> 
                     <given-names>OS</given-names>
                  </name>, <name>
                     <surname>Hewison</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3</article-title>. <source>J Immunol</source>. <year>2009</year> 
               <month>Nov</month>;<volume>183</volume>(<issue>9</issue>):<fpage>5458</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0803217</pub-id>
               <pub-id pub-id-type="pmid">19843932</pub-id>
               <issn>0022-1767</issn>
            </mixed-citation>
         </ref>
         <ref id="b93">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Samson</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Audia</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Fraszczak</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Trad</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Ornetti</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Lakomy</surname> 
                     <given-names>D</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis</article-title>. <source>Arthritis Rheum</source>. <year>2012</year> 
               <month>Nov</month>;<volume>64</volume>(<issue>11</issue>):<fpage>3788</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1002/art.34647</pub-id>
               <pub-id pub-id-type="pmid">22833233</pub-id>
               <issn>0004-3591</issn>
            </mixed-citation>
         </ref>
         <ref id="b94">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Berod</surname> 
                     <given-names>L</given-names>
                  </name>, <name>
                     <surname>Friedrich</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Nandan</surname> 
                     <given-names>A</given-names>
                  </name>, <name>
                     <surname>Freitag</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Hagemann</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Harmrolfs</surname> 
                     <given-names>K</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells</article-title>. <source>Nat Med</source>. <year>2014</year> 
               <month>Nov</month>;<volume>20</volume>(<issue>11</issue>):<fpage>1327</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3704</pub-id>
               <pub-id pub-id-type="pmid">25282359</pub-id>
               <issn>1078-8956</issn>
               <annotation>
                  <p content-type="warning">CrossMark reports an erratum (or similar issue). The CrossMark type is "erratum". Additional information can be found at https://doi.org/10.1038/nm0415-414d. (Ref. "Berod, Friedrich, Nandan, Freitag, Hagemann, Harmrolfs, et al., 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b95">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Martinez-Taboada</surname> 
                     <given-names>VM</given-names>
                  </name>, <name>
                     <surname>Blanco</surname> 
                     <given-names>R</given-names>
                  </name>, <name>
                     <surname>Fito</surname> 
                     <given-names>C</given-names>
                  </name>, <name>
                     <surname>Pacheco</surname> 
                     <given-names>MJ</given-names>
                  </name>, <name>
                     <surname>Delgado-Rodriguez</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Rodriguez-Valverde</surname> 
                     <given-names>V</given-names>
                  </name>
               </person-group>. <article-title>Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review</article-title>. <source>Semin Arthritis Rheum</source>. <year>2001</year> 
               <month>Feb</month>;<volume>30</volume>(<issue>4</issue>):<fpage>257</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1053/sarh.2001.9734</pub-id>
               <pub-id pub-id-type="pmid">11182026</pub-id>
               <issn>0049-0172</issn>
            </mixed-citation>
         </ref>
         <ref id="b96">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Elling</surname> 
                     <given-names>P</given-names>
                  </name>, <name>
                     <surname>Olsson</surname> 
                     <given-names>AT</given-names>
                  </name>, <name>
                     <surname>Elling</surname> 
                     <given-names>H</given-names>
                  </name>
               </person-group>. <article-title>Reduced CD8+ T-cell concentration in peripheral blood of patients with carotid artery stenosis: relation to arteritis temporalis</article-title>. <source>Br J Rheumatol</source>. <year>1996</year> 
               <month>Jul</month>;<volume>35</volume>(<issue>7</issue>):<fpage>649</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/35.7.649</pub-id>
               <pub-id pub-id-type="pmid">8670598</pub-id>
               <issn>0263-7103</issn>
            </mixed-citation>
         </ref>
         <ref id="b97">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Samson</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Ly</surname> 
                     <given-names>KH</given-names>
                  </name>, <name>
                     <surname>Tournier</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Janikashvili</surname> 
                     <given-names>N</given-names>
                  </name>, <name>
                     <surname>Trad</surname> 
                     <given-names>M</given-names>
                  </name>, <name>
                     <surname>Ciudad</surname> 
                     <given-names>M</given-names>
                  </name>, <etal>et al</etal>
               </person-group>. 
               <article-title>Involvement and prognosis value of CD8(+) T cells in giant cell arteritis</article-title>. <source>J Autoimmun</source>. <year>2016</year> 
               <month>Aug</month>;<volume>72</volume>:<fpage>73</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2016.05.008</pub-id>
               <pub-id pub-id-type="pmid">27236507</pub-id>
               <issn>0896-8411</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Samson, Ly, Tournier, Janikashvili, Trad, Ciudad, et al., 2016")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b98">
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <name>
                     <surname>Nadkarni</surname> 
                     <given-names>S</given-names>
                  </name>, <name>
                     <surname>Dalli</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Hollywood</surname> 
                     <given-names>J</given-names>
                  </name>, <name>
                     <surname>Mason</surname> 
                     <given-names>JC</given-names>
                  </name>, <name>
                     <surname>Dasgupta</surname> 
                     <given-names>B</given-names>
                  </name>, <name>
                     <surname>Perretti</surname> 
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression</article-title>. <source>Circ Res</source>. <year>2014</year> 
               <month>Jan</month>;<volume>114</volume>(<issue>2</issue>):<fpage>242</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.301374</pub-id>
               <pub-id pub-id-type="pmid">24158630</pub-id>
               <issn>0009-7330</issn>
            </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
